

CURRICULUM VITAE

NAME: HARTMUT W. JAESCHKE

PLACE OF BIRTH: Stuttgart, Federal Republic of Germany

CITIZENSHIP: German (permanent resident of the US since 1992)

MARITAL STATUS: Married to Dr. Mary Lynn Bajt-Jaeschke;
two sons (Andrew 12/96 and Matthew 3/99)

CURRENT ADDRESS:

BUSINESS: Department of Pharmacology, Toxicology & Therapeutics
The University of Kansas Medical Center
3901 Rainbow Blvd
MS 1018
Kansas City, KS 66160

Tel.: (913) 588 7969

E-Mail: hjaeschke@kumc.edu

CV Highlights - Table of Contents (updated October 2017)**1. Record of publications of data-based research in peer reviewed journals.**

- page 28-65: list of 392 peer-reviewed publications and book chapters (published and in press)
- page 66-72: list of 69 Highly Cited Papers (>100 citations); "h"- factor: 82 (Web of Science)

2. Presentations and invited lectures at regional, national and/or international meetings.

- page 76-80 : total of 88 invited oral presentations at National and International Scientific Meetings
- page 80-83: list of session chaired and symposia/workshops organized

3. External grant support for research.

- page 8-10: past grant support from NIH, industry
- page 10-11: current grant support: R01 grants, industry grants, P30
- page 12: completed training grants / COBRE grants

4. Peer recognition in the form of elected offices in professional societies, memberships on journal editorial boards, journal reviews, study section memberships or consultantships, and invited lectures.

- page 17-18: Membership on National and International Committees and Elected Offices
Currently: Treasurer, Intern. Society of Sinusoidal Research (2014-2019)
- page 21-24: Past and Present Editorial Board Memberships, Associate Editor, Guest Editor
Currently: Member of 16 Editorial Boards
Associate Editor Editor: *Toxicological Sciences* and 5 others
- page 25-27: Active reviewer for the following list of journals:
review load approx. >120 manuscripts per year
- page 13-16: List National and International Grant Review Committees
- page 73-76: Invited Lectures
Total of 95 invited lectures/seminars at universities/companies (national and international)

5. Previous recognition as a recipient of honors and awards.

- page 6: Honors & Awards
2017: Named Highly Cited Researcher in Pharmacology/Toxicology

6. Teaching - page 84-88: Didactic (lectures) and non-didactic (mentoring) teaching (graduate students);

EDUCATION:

1975-1983 Studies of Physiological Chemistry/Biochemistry and Toxicology
University of Tübingen
Tübingen, Federal Republic of Germany

DEGREES:

1981 Diplombiochemiker (**M.Sc., Biochemistry**)
University of Tübingen
Tübingen, Federal Republic of Germany

1983 **Ph.D., Toxicology**
University of Tübingen
Tübingen, Federal Republic of Germany

APPOINTMENTS:

1983-1986 Wissenschaftlicher Assistent
Department of Biochemistry
University of Tübingen, Tübingen, Germany

1986-1987 Research Associate
Department of Medicine
Baylor College of Medicine
Houston, Texas

1987-1988 Assistant Professor
Departments of Medicine and Pharmacology
Baylor College of Medicine
Houston, Texas

1988-1992 Research Associate Professor
Departments of Medicine and Pharmacology
Baylor College of Medicine
Houston, Texas

1991-1992 Adjunct Professor
Department of Pharmaceutics
College of Pharmacy,
University of Houston, Houston, Texas

1992 Associate Professor (tenure)
Department of Medicine
Baylor College of Medicine, Houston, Texas

- 1992-1995** Senior Scientist
Drug Metabolism Research
The Upjohn Company
Kalamazoo, Michigan
- 1994-1998** Adjunct Professor
Department of Biological Sciences
Western Michigan University
Kalamazoo, Michigan
- 1995-1998** Senior Scientist
Department of Pharmacology
Pharmacia & Upjohn, Inc.
Kalamazoo, Michigan
- 1999-2002** Professor
Department of Pharmacology & Toxicology
College of Medicine
University of Arkansas for Medical Sciences
Little Rock, Arkansas
- 2002-2006** Associate Director
Liver Research Institute
College of Medicine
University of Arizona
Tucson, Arizona
- 2002-2006** Professor (tenure)
Dept of Pharmacology and Dept of Physiology
College of Medicine
University of Arizona
Tucson, Arizona
- 2006-present** Professor (tenure)
Department of Pharmacology, Toxicology & Therapeutics
College of Medicine
The University of Kansas Medical Center
Kansas City, Kansas
- 2012-present** Chairman
Department of Pharmacology, Toxicology & Therapeutics
College of Medicine
The University of Kansas Medical Center
Kansas City, Kansas

RESEARCH INTERESTS:

1. Molecular mechanisms of inflammatory liver injury *in vivo* and *in vitro*: e.g., role of neutrophils, macrophages and lymphocytes, mechanisms of inflammatory cell injury, function and transcriptional regulation of adhesion molecules on leukocytes, endothelial cells and parenchymal cells, role of inflammatory mediators (cytokines, chemokines, complement, eicosanoids, nitric oxide).
2. Molecular mechanisms of drug-induced liver injury *in vivo* and *in vitro*: e.g., signaling mechanisms leading to mitochondrial dysfunction, role of oxidant stress and peroxynitrite formation in mechanism of cell death, mechanisms and functional significance of mitochondrial and nuclear DNA fragmentation, role of autophagy in liver injury and regeneration.
3. Translational Research in obstructive cholestasis, liver transplantation, alcoholic hepatitis, drug-induced liver injury and acute liver failure; mechanisms of acetaminophen and bile acid hepatotoxicity in overdose patients and in human hepatocytes.
4. Pathophysiology of endotoxemia and septic shock, ischemia-reperfusion injury, hemorrhagic shock, alcoholic hepatitis, multiple organ failure and systemic inflammatory response syndrome, acetaminophen-induced liver failure, intrahepatic and obstructive cholestasis, liver fibrosis and steatosis.
5. Molecular pathology of reactive oxygen- and peroxynitrite-induced diseases (role of free radicals as directly injurious agents versus their role as modulators of intracellular signal transduction pathways).
6. Molecular mechanisms of cell death (oncotic necrosis, necroptosis and apoptosis) and liver regeneration.

HONORS AND AWARDS:

- **First Independent Research Support Transition Award**
National Institute of Health, General Medicine Institute (1989 – 1994)
- **Best Paper Award in *Toxicological Sciences* (2002)**
by the Board of Publication, Society of Toxicology

Bajt, M.L., Lawson, J.A., Vonderfecht, S.L., Gujral, J.S., and Jaeschke, H.: Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor *in vivo*: Evidence for postmitochondrial processing of caspase-8. *Toxicological Sciences* 58: 109-117, 2000.
- **Offer of the *Darrell L. and Mary E. Calhoun Endowed Chair in Pharmacology, College of Pharmacy, University of Louisiana at Monroe* (2002) (offer declined)**
- **elected *Fellow of the Academy of Toxicological Sciences (ATS)* (2009; renewed 2014)**
- **Faculty Research Investigator Award, University of Kansas Medical Center (2009)**
This award is given to an investigator who displayed evidence of significant research accomplishments and a high potential for sustained productive research in the future.
- **Chancellor's Club Research Award, University of Kansas (2011)**
The Chancellors Club Research Award is presented to an individual in recognition of exceptional achievements that have had significant and long-term impact on a research field. The research should have profoundly affected later development of a field or represent a productive record of significant research. The research is expected to be of national and/or international interest.
- **elected *Fellow of the Academy of the American Association for the Study of Liver Diseases (FAASLD)* (2015)**
- **John Doull Award, Central States Chapter of the Society of Toxicology (2015)**
The John Doull award is presented each year by the Central States Chapter of the Society of Toxicology (CS-SOT) to honor the contributions of its members to the discipline of toxicology and the chapter.
- **Named a Highly Cited Researcher in Pharmacology & Toxicology (2017)**
Being a Highly Cited Researcher means that your research ranks among the top 1% most cited works in the field of Pharmacology & Toxicology during its year of publication, earning the mark of exceptional impact.

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

- **American Association for the Study of Liver Diseases (AASLD)**
- **American Physiological Society (APS)**
- **American Society of Pharmacology and Experimental Therapeutics (ASPET)**
- **Society of Toxicology (SOT)**
- **German Society of Experimental and Clinical Pharmacology and Toxicology**
- **Society of Biochemistry and Molecular Biology (Germany)**
- **International Association for the Study of Liver Disease (IASL)**
- **International Society for Hepatic Sinusoidal Research (ISHSR)**

COMPETITIVE FUNDING:**A. Principal Investigator (Past Funding):**

1. Biomedical Research Support Grant RR-05425
"Mitochondrial Alterations in Ischemia/Reflow Injury".
6/1/1988 - 3/31/1989 **Direct Costs: \$ 10,000**
2. American Heart Association, Texas Affiliate, Grant-In-Aid G-198
"Oxylradicals and Vascular Injury".
7/1/1988 - 6/30/1989 **Direct Costs: \$ 30,000**
3. NIH R29 GM 42957
"Pharmacological Interventions in Hepatic Ischemic Injury".
7/1/1989 - 6/30/1994 **Direct Costs: \$ 350,000**
4. NIH 1 R01 NIEHS 06091
"Toxicological Importance of Liver Glutathione".
7/1/1992 - 6/30/1996 **Direct Costs: \$ 750,000**
5. Cytovia Corporation
"Role of Caspases in Sepsis"
3/1/2000 – 2/28/2001 **Direct Costs: \$ 20,000**
6. COM UAMS – Pilot Project RC2000-19
"Role of Neutrophils in Hepatic Fibrogenesis".
7/1/2000 – 6/30/2001 **Direct Costs: \$ 15,000**
7. COM UAMS – Pilot Project
"Genomics: Role of HO-1 in defense against reactive oxygen-induced injury"
10/1/2001 – 9/30/2002 **Direct Costs: \$ 5,000**
8. Myogen, Inc.
"Pathophysiological consequences of BSEP inhibition"
10/1/2005 – 3/1/2006 **Direct Costs: \$ 35,360**
9. NIH 1 R01 NIAAA 12916
"Mechanisms of Neutrophil-induced Liver Toxicity"
6/1/2001 – 2/28/2007 **Direct Costs: \$ 900,000**
10. Research Institute, Bridging Grant, KUMC
"Mechanisms of Neutrophil-induced Liver Toxicity"
5/16/2007 – 11/30/2007 **Direct Costs: \$ 35,000**
Effort: 5 % (Principal Investigator)

12. NIH R56 NIAAA 12916 (Bridging Grant)
“Mechanisms of Neutrophil-induced Liver Toxicity”
7/5/2007 – 6/30/2008 **Direct Costs: \$ 225,000**
Effort: 30 % (Principal Investigator)
13. Gilead, Inc.
“Effect of Endothelin-1 Receptor Antagonists on Bile Flow and Bile Composition”
5/15/2007 – 5/15/2009 **Direct Costs: \$ 80,832**
Effort: 20 % (Principal Investigator)
14. Gilead, Inc.
“Effect of Endothelin-1 Receptor Antagonists on Hepatic Fibrosis”
9/1/2007 – 8/31/2009 **Direct Costs: \$ 30,000**
Effort: 5 % (Principal Investigator)
15. Gilead, Inc.
“Effect of Endothelin-1 Receptor Antagonists on Hepatic Fibrosis II”
1/1/2008 – 12/31/2009 **Direct Costs: \$ 11,340**
Effort: 5 % (Principal Investigator)
16. Pilot Grant, Liver Center, KUMC
“Mechanisms of Acetaminophen Hepatotoxicity in Humans”
12/1/2009 – 11/30/2010 **Direct Costs: \$ 35,000**
Effort: 20% (Principal Investigator)
17. NIH 1 R01 NIDDK 070195-5 Supplement
“Mitochondrial Dysfunction and Drug Hepatotoxicity”
1/1/2010 – 12/31/2010 **Direct Costs: \$ 80,490**
Effort: 30 % (Principal Investigator) as part of parent grant
18. NIH 1 R01 NIDDK 070195
“Mitochondrial Dysfunction and Drug Hepatotoxicity”
8/1/2005 – 7/31/2011 **Direct Costs: \$ 1,419,081**
Effort: 30 % (Principal Investigator)
19. Gilead, Inc.
“Effect of ASK Inhibitors on Hepatic Fibrosis”
9/1/2010 – 12/31/2012 **Direct Costs: \$ 35,000**
Effort: 5 % (Principal Investigator)
20. McNeil Consumer Health Care
“Acetaminophen Protein Adducts as Indicators of Liver Cell Injury”
12/1/2009 – 12/31/2012 **Direct Costs: \$ 88,680**
Effort: 10% (Principal Investigator)

21. Gilead, Inc.
 "Effect of ASK Inhibitors on Acetaminophen Hepatotoxicity"
 4/1/2011 – 3/31/2012 **Direct Costs: \$ 35,000**
 Effort: 5 % (Principal Investigator)
22. CTSA/KUMC Research Institute
 "Mechanisms of cholestatic liver injury in humans"
 3/1/2013 – 2/28/2014 **Direct Costs: \$ 25,000**
 Effort: 10% (Principal Investigator)
23. NIH R01 NIAAA 12916-06
 "Mechanisms of Neutrophil-induced Liver Toxicity"
 7/1/2008 – 6/30/2014 **Direct Costs: \$ 1,125,000**
 Effort: 30% (Principal Investigator)
24. McNeil Consumer Health Care
 "Identification of Serum Acetaminophen Protein Adducts"
 12/1/2011 – 11/30/2014 **Direct Costs: \$ 94,720**
 Effort: 10% (Principal Investigator)
25. CTSA/KUMC Research Institute
 "Detection of Biliary Strictures Post Liver Transplantation using Serum Biomarkers"
 3/1/2015 – 2/28/2016 **Direct Costs: \$ 30,000**
 Effort: 10% (Principal Investigator)

B. Co-Investigator (Past Funding):

1. NIH 2 R01 NIEHS 06091 (PI: C.W. Smith; main investigator: H.Jaeschke; renewal of my original R01 while I was in industry)
 Mechanisms of Inflammatory Liver Injury"
 12/1/96 - 11/30/2001 **Direct Costs: \$ 1,088,177**

C. Principal Investigator (Current Funding):

1. NIH 1P30 GM118247-01 (Program Director: H. Jaeschke)
 "Mechanisms of Liver Injury and Diseases"
 The major goal of this project is to create sustainable core facilities to improve the research infrastructure and provide pilot grants to promote liver research activities at KUMC.
 8/15/2016 – 7/31/2021 **Direct Costs: \$ 3,750,000**

2. 1R01 NIDDK102142-01
 “Autophagy and Drug-Induced Liver Injury” **Direct Costs: \$ 900,000**
 9/25/2014 – 5/31/2018
 Effort: 15% (Co-Principal Investigator with WX Ding)
3. Robert Hanlen-Trust /CTSA
 “Mechanisms of Alcoholic Hepatitis” **Direct Costs: \$ 150,000**
 2/1/2014 – 1/31/2018
 Effort: 10% (Principal Investigator)
4. McNeil Consumer Health Care
 “The Protective Potential of 4-Methylpyrazole against Acetaminophen Hepatotoxicity
 in Comparison to the Standard of Care N-Acetylcysteine” **Direct Costs: \$ 96,466**
 9/1/2017 – 8/31/2018
 Effort: 5% (Principal Investigator)
5. CTSA/KUMC Research Institute
 “Predictive Biomarkers in Hypoxic Hepatitis” **Direct Costs: \$ 20,000**
 7/1/2017 – 6/30/2018
 Effort: 5% (Principal Investigator)

D. Co-Investigator (Current Funding):

4. 1 R01 DK098414-01 (PI: Apte)
 “Mechanisms of Liver Regeneration after Acetaminophen-Induced Acute Liver
 Failure” **Direct Costs: \$ 1,087,500**
 3/1/2013 – 2/28/2018
 Effort: 5% (Co-Investigator)

F. Training Grants (Completed):

NIH T32 NIEHS 010952 (Program Director: J.A. Hinson)
 “Biochemical and Behavioral Mechanisms of Toxicity”
 Annual Direct Costs: \$ 551,400
 Effort: 5% as Mentor 7/1/2001 – 6/30/2006

NIH 2 T32 ES007079-26A2 (Program Director: C.D. Klaassen)
 “Training Program in Environmental Toxicology”
 Annual Direct Costs: \$267,186
 Effort: 5% as Mentor 7/01/2006 - 6/30/2011

NIH 5 P20 RR021940-02 (Program Director: C.D. Klaassen)

“Nuclear Receptors in Liver Health and Disease”

The major goal of this project is to provide infrastructure and mentor young investigators to compete for NIH program project grants.

Effort: 3% as Mentor 7/1/2006 – 6/30/2011

NIH 5 P20 GM103549-06 (Program Director: H. Jaeschke)

“Nuclear Receptors in Liver Health and Disease”

Annual Direct Costs: \$ 1,499,839

The major goal of this project is to improve the research infrastructure and mentor young investigators to compete for NIH R01 grants in the liver pathophysiology field.

Effort: 30% as PI and Mentor 7/1/2011 – 6/30/2017

- Mentor for Dr. Jim Luyendyk (received Ones Award, NIEHS in 2009)
- Mentor for Dr. Wen-Xing Ding (received R01, NIAAA, 2011)
- Mentor for Dr. Udayan Apte (received Liver Scholar Award, American Liver Foundation, 2009; received R01, NIDDK, 2013)

NIH 2 T32 ES007079-31 (Program Director: B. Hagenbuch)

“Training Program in Environmental Toxicology”

Annual Direct Costs: \$ 407,780

Effort: 5% as Assoc. Director and Mentor 7/01/2011 - 6/30/2017

SERVICE - GRANT REVIEWS

INTERNATIONAL

1994 - Reviewer for the Israel Science Foundation

1996 - Reviewer for the Hong Kong Research Grants Council

1998 - Reviewer for the Swiss National Science Foundation

2004 - Reviewer for the Hong Kong Research Grants Council

2004 - Reviewer for the Israel Science Foundation

2009 - Reviewer for Clinical Research Training Fellowships, Medical Research Council, UK.

2010 - Reviewer, Czech Science Foundation, Prague, Czech Republic.

2010 - Reviewer for Clinical Research Training Fellowships, Medical Research Council, UK.

2011 - Reviewer, Austrian Science Fund, Vienna, Austria

2011 – Reviewer, Medical Research Council, UK

2012 – Reviewer, Deutsche Forschungsgemeinschaft, Berlin, Germany

2013 - Reviewer, Deutsche Forschungsgemeinschaft, Berlin, Germany

2014 – Reviewer, PSI Foundation, Ontario, CANADA

2015 – Reviewer, PSI Foundation, Ontario, CANADA

2015 – Reviewer, Deutsche Forschungsgemeinschaft, Berlin, Germany

2016 – Reviewer, Israel Science Foundation, ISRAEL

2016 – Reviewer, Netherlands Organisation for Scientific Research (NWO)

2017 – Reviewer, Swiss National Science Foundation

NATIONAL

1989 - Ad Hoc Reviewer for the National Science Foundation

- 1994 - Ad-Hoc Reviewer, Immunology and AIDS Subcommittee of the Alcohol Biomedical Research Review Committee (ALCB3); NIAAA.
- 1995 - Reviewer for the VA Medical Research Service, Merit Review Board for Gastroenterology.
- 1995 - Member, Special Review Committee for Alcohol Research Center Grants, National Institute on Alcohol Abuse and Alcoholism.
- 1997 - Member, Special Study Section: Chemistry and Related Sciences Special Emphasis Panel (ZRG3 SSS-Z; Group 14) National Institute of Health, Small Business Innovation Research Program (SBIR) and Small Business Technology Transfer Program (STTR).
- 1998 - Reviewer for the Arkansas Science & Technology Authority
- 1999 - Reviewer for the VA Medical Research Service, Merit Review Board for Gastroenterology
- 2000 - Reviewer for the VA Medical Research Service, Merit Review Board for Gastroenterology
- 2000 - Member, Special Review Committee for Research Center Grants (Special Emphasis Panel, ZDK1 GRB-7), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). PPG of Dr. Lemasters.
- 2001 - Member, Special Review Committee for Research Center Grants (Special Emphasis Panel, ZDK1 GRB-7), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). PPG of Dr. Granger.
- 2002 - Chairman, Special Emphasis Panel for the Review of Conference Grants, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- 2002 - Reviewer for the VA Medical Research Service, Merit Review Board for Gastroenterology
- 2003 - Member, Special Review Committee for Alcohol Research Center Grants, National Institute on Alcohol Abuse and Alcoholism (NIAAA). Center Grant of Dr. Tsukamoto.
- 2004 - Member, Special Emphasis Panel ZAA1-DD14 for Grants of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- 2004 - Reviewer for the NIH Action Plan for Liver Disease Research, Chapter 5 (Cell Injury, Repair, Fibrosis and Inflammation), Liver Disease Research Branch, NIDDK.

- 2004 - Ad-hoc Member of *Hepatobiliary Pathophysiology* (HBPP) Study Section, National Institute of Health.
- 2005 - Member, Special Review Committee for Alcohol Research Center Grants, National Institute on Alcohol Abuse and Alcoholism (NIAAA). Center Grant of Dr. McClain.
- 2006 - Reviewer for Merck Mechanisms Postdoctoral Award, Mechanisms Specialty Section, Society of Toxicology.
- 2006 - Reviewer for Pilot Proposals for the Center for Environmental and Rural Health at Texas A&M University.
- 2006 - Member, Special Emphasis Panel ZRG1 DIG F, National Institutes of Health (Grant review for Study Section Members).
- 2007 - Member, Special Emphasis Panel/Scientific Review Group 2007/10 ZAA1 BB (90) for Center Grants, National Institutes of Health, NIAAA.
- 2007 - Member, Special Emphasis Panel ZRG1 DIG F (02) M, National Institutes of Health (Grant review for Study Section Members).
- 2008 - Member, Special Review Committee for Alcohol Research Center Grants (2008/10 ZAA1 JJ 97P) National Institute on Alcohol Abuse and Alcoholism (NIAAA). Center Grant of Dr. Tsukamoto.
- 2008 – 2013 Standing Member of the *Hepatobiliary Pathophysiology* (HBPP) Study Section, National Institute of Health.
- 2010 - Member, Special Review Committee for Resource Core Alcohol Research Center (P30) National Institute on Alcohol Abuse and Alcoholism (NIAAA). Center Grant of Dr. Hoek.
- 2011 - Reviewer for NIH Review Meeting “Mechanistic Research on CAM Natural Products (R01)” held by the National Center for Complementary and Alternative Medicine (NCCAM / NIH) together with the Office of Dietary Supplements (ODS / NIH) and the National Cancer Institute (NCI / NIH) special study section.
- 2011 – Reviewer for NIH Review Panel (NIDDK) to evaluate the competing renewal program project grant application entitled “Liver Cell Membrane Protein-Expression and Function” submitted by Dr. Allan W. Wolkoff, Albert Einstein College of Medicine.
- 2012 – Reviewer for Kentucky Science & Engineering Foundation, Louisville, Kentucky.

- 2013 - Member, Special Review Committee for Resource Core Alcohol Research Center (P30) National Institute on Alcohol Abuse and Alcoholism (NIAAA). Center Grant of Dr. Friedman.
- 2013 - Reviewer, The Louisiana Board of Regents Research Competitiveness Subprogram (RCS).
- 2014 – Reviewer, Botanical Dietary Supplement Research Centers (BDSRC) (P50), NIH, National Center of Complementary and Alternative Medicine (NCCAM).
- 2015 – Reviewer, Pilot Centers for Precision Disease Modeling (U54), NIH, Interdisciplinary Molecular Sciences and Training (IMST).
- 2015 – NIH Pilot Study (CSR) to evaluate relative quality of grant applications across study sections within Integrated Review Groups at CSR.
- 2015 – Reviewer, Department of Defense Grants
- 2016 - *Ad-hoc* Member of Hepatobiliary Pathophysiology (HBPP) Study Section, National Institute of Health (June study section).
- 2016 *Ad-hoc* Member of Hepatobiliary Pathophysiology (HBPP) Study Section, National Institute of Health (October study section).
- 2017 Member, NIH Review Panel, ZRG1 DKUS-P (03), Special Emphasis Panel for member conflict applications related to topics in Hepatology.
- 2018 Member, NIH/NIDDK Review Panel, PAR-17-123 entitled “Biomarkers for diabetes, digestive, kidney and urological diseases using biosamples from the NIDDK Repository (R01).

SERVICE - OTHERS***INTERNATIONAL***

- 1996 – 2010 Member of the International Scientific Organizing Committee of the Kupffer Cell Foundation, Biennial Meetings
1998: Christchurch, New Zealand
2000: Southampton, Great Britain
2002: Tucson, Arizona, USA
2004: Bilbao, Spain
2006: Niigata, Japan
2008: Tromso, Norway
2010: Pasadena, CA, USA
- 1998 – 2000 Member of the Scientific Program Committee of the 5th World Congress on Trauma, Shock, Inflammation and Sepsis (March 2000, Munich, Germany).
- 2000 Member, Poster Judge Panel, 10th Int. Symposium on Cells of the Hepatic Sinusoid, Southampton, UK.
- 2000 – 2001 Member of the Scientific Committee of the 2nd International Conference on Hepatic and Splanchnic Circulation in Health and Disease, Dunedin, New Zealand.
- 2001 Member of the Abstract Review Committee, 6th Congress of the International Society for Organ Sharing, Nagoya, Japan.
- 2002 Member of the Abstract Review Committee, 10th Annual Congress of the Union of the European Gastroenterological Societies (UEGW) - Geneva, Switzerland.
- 2009 – 2013 Secretary/Treasurer, International Society for Hepatic Sinusoidal Research (ISHSR). (elected office)
- 2014 – 2019 Treasurer, International Society for Hepatic Sinusoidal Research (ISHSR). (elected office).
- 2015 External PhD Thesis Examiner, candidate: John Mach), University of Sydney, Australia.
- 2017 External PhD Thesis Examiner (candidate: Rowan F. van Golen), University of Amsterdam, The Netherlands

NATIONAL

- 1999 - 2001 Hepatotoxicity Steering Committee, White Paper Preclinical Subcommittee (FDA, PhRMA, AASLD)
- 2002 – 2005 Member, Abstract Review Committee, American Association for the Study of Liver Diseases (AASLD).
- 2005 Member, Abstract Review Committee, 12th Annual Meeting of the Society for Free Radical Biology and Medicine (SFRM).
- 2007 - 2011 Board of Publications, Society of Toxicology (SOT) (Chair: 2009-2011)
- 2007 – 2008 Vice-President, Central States Regional Chapter of the Society of Toxicology (CS-SOT) (elected office)
- 2008 – 2009 President, Central States Regional Chapter of the Society of Toxicology (CS-SOT) (elected office)
- 2009 – 2010 Past-President, Central States Regional Chapter of the Society of Toxicology (CS-SOT) (elected office)
- 2008 – 2010 Local Organizing Committee, 15th International Symposium on Cells of the Hepatic Sinusoid, Pasadena, CA
- 2008 Ad-hoc Member, Abstract Review Committee, American Association for the Study of Liver Diseases (AASLD).
- 2009 Member, Abstract Review Committee, 15th Annual International Congress of the International Liver Transplant Society, New York, NY.
- 2010 – 2013 Member, Journals Publication Committee, American Association for the Study of Liver Diseases (AASLD)
- 2015 - present Member, Abstract Review Committee, American Association for the Study of Liver Diseases (AASLD).
- 2015 – present Member, External Advisory Committee, COBRE Center for Studies of Host Response to Cancer Therapy. University of Arkansas for Medical Sciences, Little Rock, AR.
- 2016 Member, Abstract Review Committee, Carl Smith Award, Mechanism Specialty Section, Society of Toxicology.
- 2017-present Councilor, Clinical and Translational Toxicology Specialty Section, Society of Toxicology.

INDUSTRY AND UNIVERSITY COMMITTEES**The Upjohn Company**

1994 – 1996 Postdoctoral Program Committee, Pharmacia & Upjohn, Inc.

1995 – 1998 Group Leader, *In Vivo* Pharmacology, Integrin Team, Pharmacia & Upjohn.

University of Arkansas for Medical Sciences

1999 – 2002 Member, Graduate Council, UAMS

1999 – 2002 Member, Faculty Subcommittee of the Graduate Council, UAMS (Chair: 2001-2002).

2000, 2001 Member, Faculty Search Committee, Dept. of Pharmacology and Toxicology, UAMS.

2001 – 2002 Member, Task Force of Graduate Council to Review Guidelines for Admission Policies for Graduate School, UAMS.

University of Arizona

2002 - 2006 Associate Director, Liver Research Institute

2004 – 2006 Member, Executive Committee, Graduate Program in Medical Pharmacology, Dept. of Pharmacology.

2005 – 2006 Member, Admissions Committee, Medical Pharmacology Program, Dept. of Pharmacology.

University of Kansas Medical Center

2007, 2009, 2011 Member, Faculty Search Committee. Dept. of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center

2007 – 2011 Member, Intramural Advisory Committee, Liver Center.

2007 – present Member, Graduate Committee, Department of Pharmacology, Toxicology & Therapeutics.

2007 – 2011 Member, Departmental Promotion and Tenure Committee, Department of Pharmacology, Toxicology & Therapeutics.

2008 – 2011 Member, IGPBS Advisory Board

- 2008 – 2011 Member, KUMC Graduate Council
- 2008 – 2011 Graduate School Advisor, Department of Pharmacology, Toxicology & Therapeutics.
- 2010 – 2011 Member, Strategic Planning Work Group (Driving Discovery and Innovation), University of Kansas.
- 2011 – 2016 PI, P20 COBRE grant – Steering Committee
- 2012 – present Member, Executive Committee, Liver Center, KUMC.
- 2012 Member, EVC Transition Team –Research, KUMC
- 2013 Member, Internal Study Section: Lied Grants, Diabetes Pilot Grants and KL2 Grants
- 2015 Member, Internal Review Committee, BRTP Graduate Student Awards
- 2016 – present PI, P30 COBRE grant – Steering Committee, Core Advisory Committee, Pilot Grant Advisory Committee
- 2017- present Member (as Basic Science Chair Representative), Executive Committee, School of Medicine
- 2017 Member, Internal Review Panel: Lied Grants, Clinical Pilots and Translational Pilot Grants

EDITORIAL ACTIVITIES

CURRENT EDITORIAL BOARD APPOINTMENTS:

1997 - present	Shock
2005 - present	World Journal of Gastroenterology
2007 – present	Journal of Hepatology
2009 - present	Hepatology
2009 - present	Hepatic Medicine: Evidence and Research
2009 - present	World Journal of Gastrointestinal Pathophysiology
2010 – present	World Journal of Hepatology
2010 – present	World Journal of Gastrointestinal Pharmacology and Therapeutics
2011 – present	Journal of Gastroenterology and Hepatology Research
2012 – present	Conference Papers in Medicine (Pathology)
2014 – present	Edorium Journal of Pharmacology
2015 – present	Toxics
2015 - present	Gene Expression: the Journal of Basic Liver Research
2016 – present	Journal of Clinical and Translational Hepatology
2016 – present	Reactive Oxygen Species
2016 – present	American Journal of Pathology

PREVIOUS EDITORIAL BOARD APPOINTMENTS:

- 1998 – 2001 **Hepatology**
- 2001 – 2004 **Journal of Hepatology**
- 2002 – 2004 **Member, *Beyond the Journal Committee*, Journal of Hepatology**
- 2004 – 2007 **Toxicology Letters**
- 2002 – 2007 **Gastroenterology**
- 2002 – 2009 **American Journal of Physiology – Gastrointestinal and Liver
Physiology**
- 1998 – 2014 **Toxicological Sciences**
- 2014 – 2016 **Journal of Clinical and Translational Research**

EDITORSHIPS

2001 – 2006	Section Editor “Hepatology Elsewhere”, Hepatology
2002 – 2006	Associate Editor, Hepatology
2007 – 2012	Associate Editor, Liver International
2008 - present	Associate Editor, BioMed Research International
2014 – present	Associate Editor, Inflammation & Cell Signaling
2014 – present	Associate Editor, Toxicological Sciences
2014 – present	Editor, MedCrave Online Journal of Toxicology
2015 – present	Editor, MedCrave Pharmacy & Pharmacology International Journal
2016 – present	Associate Editor, Journal of Clinical and Translational Research

GUEST AND FORUM EDITOR

2001 - 2002	Forum Editor, Antioxidants & Redox Signaling
2001, 2002	Guest Editor, Gastroenterology
2012 - 2013	Section Editor, <i>Mitochondrial Dysfunction and Disease</i> , Current Pathobiology Reports
2014	Guest Editor, Special Issue: <i>Innovative pharmacological/therapeutic approaches against hepatic ischemia-reperfusion injury</i> . BioMed Research International
2016	Guest Editor, Special Issue: <i>New Insights into the Pharmacological Control of Oxidative Stress</i> . Oxidative Medicine and Cellular Longevity
2016	Guest Editor, Special Issue: <i>Mechanisms of Drug-induced Hepatotoxicity: A Translational Research Perspective</i> . Journal of Clinical and Translational Research
2017	Guest Editor, Proceedings of the National Academy of Sciences
2018-2019	<i>Hepatotoxicity</i> (Ramachandran, A., and Jaeschke, H., volume editors); Series: <i>Advances in Pharmacology</i> (Enna, S., Series Editor).

ACTIVE REVIEWER FOR THE FOLLOWING JOURNALS:

1. Biochemical Pharmacology
2. Journal of Clinical Investigation
3. American Journal of Physiology (Gastroenterology and Liver Physiology; Cell Physiology; Regulatory, Integrative, Comparative Physiology; Endocrinology & Metabolism)
4. Hepatology
5. Journal of Pharmacology and Experimental Therapeutics
6. Gastroenterology
7. American Journal of Pathology
8. Toxicology Letters
9. Life Sciences
10. Journal of Hepatology
11. Journal of Leukocyte Biology
12. Liver International
13. Biomedicine & Pharmakotherapie
14. Toxicology and Applied Pharmacology
15. Transplantation
16. Digestive Diseases and Sciences
17. Free Radical Biology & Medicine
18. Chemico-Biological Interactions
19. FASEB Journal
20. Molecular and Cellular Biochemistry
21. Journal of Immunology
22. Shock
23. Biochimica Biophysica Acta
24. Liver Transplantation
25. Journal of Gastroenterology and Hepatology
26. Journal of Vascular Research
27. Journal of Laboratory and Clinical Medicine
28. European Journal of Clinical Chemistry and Clinical Biochemistry
29. Immunology Today
30. Clinical Immunology and Immunopathology
31. Laboratory Investigation
32. Toxicological Sciences
33. Experimental Cell Research
36. Drug Metabolism Reviews
37. Archives of Biochemistry and Biophysics
38. Cellular Immunology
39. European Surgical Research
40. Endocrinology
41. Gut (International Journal of Gastroenterology and Hepatology)
42. Clinical and Experimental Pharmacology and Physiology
43. Journal of Toxicology and Environmental Health
44. Journal of Cellular Physiology
45. Alcoholism: Clinical & Experimental Research
46. Autonomic & Autocoid Pharmacology
47. Inflammation Research
48. Microcirculation
49. Annals of Surgery
50. Chemical Research in Toxicology
51. Digestion
52. Expert Opinions on Therapeutic Targets
53. Expert Opinions on Drug Safety
54. British Journal of Surgery
55. Critical Care Medicine

56. Pathology – Research and Practice
57. Experimental Biology and Medicine
58. Immunity
59. Comparative Hepatology
60. World Journal of Gastroenterology
61. Human & Experimental Toxicology
62. BCM Gastroenterology
63. European Journal of Pharmacology
64. Journal of Physiology
65. Canadian Journal of Physiology and Pharmacology
66. American Journal of Transplantation
67. PLoS Medicine
68. Histochemistry and Cell Biology
69. Pflugers Archiv-European Journal of Physiology
70. British Journal of Pharmacology
71. Journal of Surgical Research
72. Nitric Oxide: Biology and Chemistry
73. Pharmacological Reviews
74. Biological Reviews
75. Alcohol & Alcoholism
76. Environmental Toxicology and Pharmacology
77. Expert Reviews of Gastroenterology & Hepatology
78. American Journal of Transplantation
79. American Journal of Surgery
80. Pharmacogenetics and Genomics
81. Nature Biotechnology
82. World Journal of Gastrointestinal Pathophysiology
83. Fundamental and Clinical Pharmacology
84. EMBO Reports
85. BMC Physiology
86. Cellular and Molecular Biology Letters
87. Pharmacological Research
88. Experimental and Molecular Pathology
89. Human Genetics
90. Neurotoxicity Research
91. The Lancet
92. Apoptosis
93. Journal of Hazardous Materials
94. Open Access Emergency Medicine
95. Trends in Pharmacological Sciences
96. Clinical Sciences
97. Yonsei Medical Journal
98. Plos One
99. Reviews on Recent Clinical Trials
100. Mediators of Inflammation (Hindawi)
101. Gastroenterology and Hepatology Research
102. HPB Surgery
103. African Journal of Pharmacy and Pharmacology
104. Frontiers Mitochondria
105. Science Asia
106. Future Medicine –Biomarkers
107. Clinical Nutrition
108. Indian Journal of Anesthesia
109. Stem Cell Research
110. Immunopharmacology and Immunotoxicology
111. Food and Chemical Toxicology

112. Toxicon
113. Open Vet Journal
114. Naunyn Schmiedeberg's Archives of Pharmacology
115. Journal of Pharmaceutical and Biomedical Analysis
116. Redox Report
117. Jordan Journal of Biological Sciences
118. Journal of Food Science
119. Xenobiotica

Review Load: Approx. >120 Manuscripts per Year

PUBLICATIONS

1. Wendel, A., **Jaeschke, H.**, and Gloger, M.: Drug-induced lipid peroxidation in mice II: Protection against paracetamol-induced liver necrosis by intravenous liposomally entrapped glutathione. *Biochemical Pharmacology* 31: 3601-3605, 1982.
2. Wendel, A., and **Jaeschke, H.**: Drug-induced lipid peroxidation in mice III: Glutathione content of liver, kidney and spleen after intravenous administration of free and liposomally entrapped glutathione. *Biochemical Pharmacology* 31: 3607-3611, 1982.
3. Wendel, A., and **Jaeschke, H.**: Differential hepatoprotection against paracetamol-induced liver necrosis in mice by free and liposomally-entrapped glutathione. *In: Functions of Glutathione - Biochemical, Physiological, Toxicological and Clinical Aspects.* (Larsson A, Orrenius S, Holmgren A, Mannervik B, eds.) Raven Press, New York, 1983, pp. 139-147.
4. **Jaeschke, H.**, Krell, H., and Pfaff, E.: No increase of biliary permeability in ethinylestradiol-treated rats. *Gastroenterology* 85: 808-814, 1983.
5. Krell, H., **Jaeschke, H.**, Hoeke, H., and Pfaff, E.: Bile secretion in hemoglobin-free perfused rat liver. *Hoppe-Seyler's Zeitschrift für Physiologische Chemie* 365: 1115-1122, 1984.
6. **Jaeschke, H.**, and Wendel, A.: Diurnal fluctuation and pharmacological alteration of mouse organ glutathione content. *Biochemical Pharmacology* 34: 1029-1033, 1985.
7. **Jaeschke, H.**, and Wendel, A.: Manipulation of mouse organ glutathione contents I: Enhancement by oral administration of butylated hydroxyanisole and butylated hydroxytoluene. *Toxicology* 36: 77-85, 1985.
8. Krell, H., **Jaeschke, H.**, and Pfaff, E.: Regulation of canalicular bile formation by alpha-adrenergic action and by external ATP in the isolated perfused rat liver. *Biochemical Biophysical Research Communications* 131: 139-145, 1985.
9. **Jaeschke, H.**, and Wendel, A.: Manipulation of mouse organ glutathione contents II: Time and dose-dependent induction of the glutathione conjugation system by phenolic antioxidants. *Toxicology* 39: 59-70, 1986.
10. **Jaeschke, H.**, Kleinwaechter, C., and Wendel, A.: The role of acrolein in allyl alcohol-induced lipid peroxidation and liver cell damage in mice. *Biochemical Pharmacology* 36: 51-57, 1987.

11. **Jaeschke, H.**, Krell, H., and Pfaff, E.: Quantitative estimation of transcellular and paracellular pathways of biliary sucrose in isolated perfused rat liver. *Biochemical Journal* 241: 635-640, 1987.
12. Krell, H., Metz, J., **Jaeschke, H.**, Hoeke, H., and Pfaff, E.: Drug-induced intrahepatic cholestasis: Characterization of different pathomechanisms. *Archives of Toxicology* 60: 124-130, 1987.
13. Bridges, J.W., Dieter, H.H., Guengerich, F.P., **Jaeschke, H.**, Klaasen, C.D., Mason, R.P., Moldeus, P., Nordberg, M., Reddy, J.K., Sies, H., and Uehleke, H.: Metabolism and molecular interactions related to toxicity. In: Mechanisms of Cell Injury: Implications for Human Health, Dahlem Konferenzen. (Fowler, B.A., ed.) John Wiley and Sons Ltd., Chichester, 1987, pp. 353-382.
14. **Jaeschke, H.**, Trummer, E., and Krell, H.: Increase in biliary permeability subsequent to intrahepatic cholestasis by estradiol valerate in rats. *Gastroenterology* 93: 533-538, 1987.
15. **Jaeschke, H.**, Werner, C., and Wendel, A.: Disposition and hepatoprotection by phosphatidyl choline liposomes in mouse liver. *Chemico Biological Interactions* 64: 127-137, 1987.
16. Mitchell, J.R., Smith, C.V., Hughes, H., Lenz, M., **Jaeschke, H.**, Shappell, S., Michael, L., and Entman, M.L.: No evidence for reactive oxygen damage in ischemia-reflow injury. *Transactions of the Association of American Physicians* 100: 54-61, 1987.
17. **Jaeschke, H.**, Smith, C.V., and Mitchell, J.R.: Hypoxic damage generates reactive oxygen species in isolated perfused rat liver. *Biochemical Biophysical Research Communications* 150: 568-574, 1988.
18. **Jaeschke, H.**, Smith, C.V., and Mitchell, J.R.: Reactive oxygen species and ischemia-reflow injury in isolated perfused rat liver. *Journal of Clinical Investigations* 81: 1240-1246, 1988.
19. Wendel, A., and **Jaeschke, H.**: Influences of selenium deficiency and glutathione status on liver metabolism. In: Cellular Antioxidant Defense Mechanisms, Vol. II. (Chow CK, ed), CRC Press, Boca Raton, 1988, pp. 133-147.
20. Wendel, A., **Jaeschke, H.**, and Kleinwaechter, C.: Xenobiotic-induced lipid peroxidation and glutathione status of mouse liver. In: Lipid Peroxidation in Biological Systems. (Sevanian, A., ed), AOCS Press, Champaign, Ill., 1988, pp. 71-83.
21. **Jaeschke, H.**, and Wendel, A.: Choleresis and increased biliary efflux of glutathione induced by phenolic antioxidants in rats. *Toxicology* 52: 225-235, 1988.

22. Smith, C.V. and **Jaeschke, H.**: Effect of acetaminophen on hepatic content and biliary efflux of glutathione disulfide in mice. *Chemico Biological Interactions* 70: 241-248, 1989.
23. **Jaeschke, H.** and Mitchell, J.R.: Mitochondria and xanthine oxidase both generate reactive oxygen species after hypoxic damage in isolated perfused rat liver. *Biochemical Biophysical Research Communications* 160: 140-147, 1989.
24. Spalding, D.J.M., Mitchell, J.R., **Jaeschke, H.** and Smith, C.V.: Diquat hepatotoxicity in the Fischer-344 rat: The role of covalent binding to tissue proteins and lipids. *Toxicology and Applied Pharmacology* 101: 319-327, 1989.
25. Ammon, H.P.T., Klumpp, S., Fuss, A., Verspohl, E.J., **Jaeschke, H.**, Wendel, A. and Mueller, P.: A possible role of plasma glutathione in glucose-mediated insulin secretion: *In vitro* and *in vivo* studies in rats. *Diabetologia* 32: 797-800, 1989.
26. **Jaeschke, H.**: The pathophysiological significance of increased tight-junctional permeability during oestrogen cholestasis. *Biochemical Journal (Letter)* 266: 620-622, 1990.
27. **Jaeschke, H.**: Glutathione disulfide as index of oxidant stress in rat liver during hypoxia. *American Journal of Physiology* 258: G499-G505, 1990.
28. **Jaeschke, H.** and Mitchell, J.R.: The use of isolated perfused organs in hypoxia and ischemia/reflow oxidant stress. *Methods in Enzymology* 186: 752-759, 1990.
29. Hughes, H., **Jaeschke, H.**, and Mitchell, J.R.: Measurement of oxidant stress *in vivo*. *Methods in Enzymology* 186: 681-685, 1990.
30. Kehrer, J.P., Jones, D.P., Lemasters, J.J., Farber, J.L. and **Jaeschke, H.**: Mechanisms of hypoxic cell injury. *Toxicology and Applied Pharmacology* 106: 165-178, 1990.
31. **Jaeschke, H.**, Farhood, A., and Smith, C.W.: Neutrophils contribute to ischemia/reperfusion injury in rat liver *in vivo*. *FASEB Journal* 4: 3355-3359, 1990.
32. **Jaeschke, H.**: Glutathione disulfide formation and oxidant stress during acetaminophen - induced hepatotoxicity in mice *in vivo*: The protective effect of allopurinol. *Journal of Pharmacology and Experimental Therapeutics* 255: 935-941, 1990.
33. **Jaeschke, H.**, Benzick, A.E., Smith, C.V. and Mitchell, J.R.: The pathophysiological significance of reactive oxygen formation in rat liver. *In: Biological Reactive Intermediates IV* (C.M. Witmer, R.R. Snyder, D.J. Jollow, G.F. Kalf, J.J. Kocsis, and I.G. Sipes, eds.) Plenum Publ. Corp., New York, 1990, pp. 295-298.

34. Ballard, K.D., Raftery, M.J., **Jaeschke, H.**, and Gaskell, S.J.: Multiple scan modes in the hybrid tandem mass spectrometric screening and characterization of the glutathione conjugate of 2-furamide. *Journal of the American Society of Mass Spectrometry* 2: 55-68, 1991.
35. **Jaeschke, H.** and Farhood, A.: Neutrophil and Kupffer cell - induced oxidant stress and ischemia-reperfusion injury in rat liver *in vivo*. *American Journal of Physiology* 260: G355-G362, 1991.
36. **Jaeschke, H.**: Vascular oxidant stress and hepatic ischemia/reperfusion injury. *Free Radical Research Communications* 12-13: 737-743, 1991.
37. **Jaeschke, H.**, Smith, C.W., and Farhood, A.: The pathophysiological role of Kupffer cells and neutrophils in hepatic ischemia/reperfusion *in vivo*. *In: Cells of the Hepatic Sinusoid*, Vol. III (E. Wisse, D.L. Knook, and R.S. McCuskey; eds), Kupffer Cell Foundation, Rijswijk, 1991, pp. 367-370.
38. **Jaeschke, H.**: Hepatic glutathione release protects liver cells against Kupffer cell-induced oxidant stress. *In: Cells of the Hepatic Sinusoid*, Vol. III (E. Wisse, D.L. Knook, and R.S. McCuskey; eds), Kupffer Cell Foundation, Rijswijk, 1991, pp. 381-383.
39. **Jaeschke, H.**: Reactive oxygen and ischemia/reperfusion injury of the liver (Review). *Chemico Biological Interactions* 79: 115-136, 1991.
40. **Jaeschke, H.**, Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. *Free Radical Research Communications* 15: 277-284, 1991.
41. **Jaeschke, H.**, Farhood, A., and Smith, C.W.: Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18 - dependent mechanism. *American Journal of Physiology* 261: G1051-G1056, 1991.
42. **Jaeschke, H.**, Kleinwaechter, C., and Wendel, A.: NADH-dependent reductive stress and ferritin-bound iron in allyl alcohol-induced lipid peroxidation *in vivo*: the protective effect of vitamin E. *Chemico Biological Interactions* 81: 57-68, 1992.
43. Hughes, H., Farhood, A., and **Jaeschke, H.**: The role of leukotriene B₄ in the pathogenesis of hepatic ischemia-reperfusion injury in the rat. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 45: 113-119, 1992.
44. **Jaeschke, H.**, Smith, C.W., Hughes, H., and Farhood, A.: The role of neutrophils in hepatic ischemia/reperfusion injury. *In: The Molecular Basis of Oxidative Damage by Leukocytes* (A. Jesaitis and E.A. Dratz, eds.) CRC Press, Boca Raton, Florida, 1992, pp 341-345.

45. **Jaeschke, H.**, Schini, V.B., and Farhood, A.: Role of nitric oxide in the oxidant stress during ischemia-reperfusion injury of the liver. *Life Sciences* 50: 1797-1804, 1992.
46. **Jaeschke, H.**: Enhanced sinusoidal glutathione efflux during endotoxin-induced oxidant stress *in vivo*. *American Journal of Physiology* 263: G60-G68, 1992.
47. Raftery, M.J., Justesen, U., **Jaeschke, H.**, and Gaskell, S.J.: Mass spectrometric quantification of cysteine-containing leukotrienes in rat bile using [¹³C]-labeled internal standards. *Biological Mass Spectrometry* 21: 509-516, 1992.
48. **Jaeschke, H.**, Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Superoxide generation by neutrophils and Kupffer cells during *in vivo* reperfusion after hepatic ischemia in rats. *Journal of Leukocyte Biology* 52: 377-382, 1992.
49. **Jaeschke, H.**, and Benzick, E.A.: Pathophysiological consequences of enhanced intracellular superoxide formation in isolated perfused rat liver. *Chemico Biological Interactions* 84: 55-68, 1992.
50. **Jaeschke, H.**: Invited Commentary on "Isolated cells in the study of the molecular mechanisms of reperfusion injury". *Toxicology Letters* 63: 107-110, 1992.
51. **Jaeschke, H.**, Raftery, M.J., Justesen, U., and Gaskell, S.J.: Serum complement mediates endotoxin-induced cysteinyl leukotriene formation in rats *in vivo*. *American Journal of Physiology* 263: G947-G952, 1992.
52. **Jaeschke, H.**, Bautista, A.P., Spolarics, Z., Farhood, A., and Spitzer, J.J.: Enhanced generation of superoxide by complement-stimulated Kupffer cells and priming of neutrophils during the initial reperfusion phase after hepatic ischemia. *In: Oxygen Radicals* (K. Yagi, M. Kondo, E. Niki, T. Yoshikawa, eds.), Excerpta Medica, Amsterdam, 1992, pp. 509-512.
53. Bautista, A.P., Deaciuc, I.V., **Jaeschke, H.**, Spolarics, Z., and Spitzer, J.J.: Hepatic responses to bacterial endotoxin. *In: Pathophysiology of Shock, Sepsis, and Organ Failure* (G. Schlag, H. Redl, eds.), Springer Verlag, Berlin, 1993, pp. 915-934.
54. **Jaeschke, H.**, Farhood, A., Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. *American Journal of Physiology* 264: G801-G809, 1993.
55. **Jaeschke, H.**, Farhood, A., Bautista, A.P., Spolarics, Z., Spitzer, J.J., and Smith, C.W.: Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. *Hepatology* 17: 915-923, 1993.

56. Bautista, A.P., Spolarics, Z., **Jaeschke, H.**, Smith, C.W., and Spitzer, J.J.: Monoclonal antibody against the CD18 adhesion molecules stimulates glucose uptake by the liver and non-parenchymal cells. *Hepatology* 17: 924-931, 1993.
57. **Jaeschke, H.**: Therapeutic potential of glutathione in hepatic ischemia-reperfusion injury. *Transplantation* (Letter) 56: 256-257, 1993.
58. **Jaeschke, H.**, Bautista, A.P., Spolarics, Z., Farhood, A., Spitzer, J.J., and Smith, C.W.: Neutrophils and Kupffer cells generate reactive oxygen during reperfusion after hepatic ischemia: The protective effect of an anti-CD11b monoclonal antibody. *In: Cells of the Hepatic Sinusoid*, Vol. 4 (D.L. Knook, E. Wisse; eds), Kupffer Cell Foundation, Leiden, 1993, pp. 413-416.
59. **Jaeschke, H.**, Raftery, M.J., Justesen, U., and Gaskell, S.J.: Complement-mediated cysteinyl leukotriene formation and hepatic ischemia during endotoxemia in rats *in vivo*. *In: Cells of the Hepatic Sinusoid*, Vol. 4 (D.L. Knook, E. Wisse; eds), Kupffer Cell Foundation, Leiden, 1993, pp. 326-328.
60. Witthaut, R., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Complement and tumor necrosis factor- α contribute to Mac-1 (CD11b/CD18) upregulation and systemic neutrophil activation during endotoxemia *in vivo*. *Journal of Leukocyte Biology* 55: 105-111, 1994.
61. Bautista, A.P., Spolarics, Z., **Jaeschke, H.**, Smith, C.W., and Spitzer, J.J.: Anti-neutrophil monoclonal antibody (1F12) alters superoxide anion release by neutrophils and Kupffer cells. *Journal of Leukocyte Biology* 55: 328-335, 1994.
62. **Jaeschke, H.**, Farhood, A., and Smith, C.W.: Contribution of complement-stimulated hepatic macrophages and neutrophils to endotoxin-induced liver injury in rats. *Hepatology* 19: 973-979, 1994.
63. Mathews, W.R., Guido, D.M., Fisher, M.A., and **Jaeschke, H.**: Lipid peroxidation as molecular mechanism of liver cell injury during reperfusion after ischemia. *Free Radical Biology and Medicine* 16: 763-770, 1994.
64. Liu, P., Vonderfecht, S.L., Fisher, M.A., McGuire, G.M., and **Jaeschke, H.**: Priming of phagocytes for reactive oxygen production during hepatic ischemia and reperfusion increases the susceptibility for endotoxin-induced liver injury. *Circulatory Shock* 43: 9-17, 1994.
65. **Jaeschke, H.**: Pathogenetische Mechanismen des akuten Leberversagens (Invited Review). *Zentralblatt für Chirurgie* 119: 309-316, 1994.
66. **Jaeschke, H.**: Pathophysiology of hepatic ischemia-reperfusion injury: The role of complement activation (Invited Editorial). *Gastroenterology* 107: 583-586, 1994.

67. Liu, P., Vonderfecht, S.L., McGuire, G.M., Fisher, M.A., Farhood, A., and **Jaeschke, H.**: The 21-aminosteroid tirilazad mesylate protects in a model of endotoxin shock and acute liver failure in rats. *Journal of Pharmacology and Experimental Therapeutics* 271: 438-445, 1994.
68. Liu, P., Fisher, M.A., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Beneficial effect of extracellular glutathione against reactive oxygen-mediated reperfusion injury in the liver. *Circulatory Shock* 43: 64-70, 1994.
69. Chang, J., **Jaeschke, H.**, and Randerath, K.: Effect of Ni(II) on tissue hydrogen peroxide content in mice as inferred from glutathione and glutathione disulfide measurements. *Life Sciences* 55: 1789-1796, 1994.
70. Liu P., McGuire, G.M., Fisher, M.A., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. *Shock* 3: 56-62, 1995.
71. **Jaeschke, H.**: The inflammatory response after hepatic ischemia-reperfusion (Review). In: *Cell Biology of Trauma*, (C. Oliver and J.J. Lemasters, eds.), CRC Press, Boca Raton, 1995, pp. 127-147.
72. Farhood, A., McGuire, G.M., Manning, A.M., Miyasaka, M., Smith, C.W., and **Jaeschke, H.**: Intercellular adhesion molecule-1 (ICAM-1) gene expression and its role in neutrophil-induced ischemia-reperfusion injury in the liver. *Journal of Leukocyte Biology* 57: 368-374, 1995.
73. **Jaeschke, H.**: Mechanisms of oxidant stress-induced acute tissue injury (Invited Review). *Proceedings of the Society of Experimental Biology and Medicine* 209: 104-111, 1995.
74. Essani, N.A., McGuire, G.M., Manning, A.M., and **Jaeschke, H.**: Differential induction for mRNA of ICAM-1 and selectins in hepatocytes, Kupffer cells and endothelial cells during endotoxemia. *Biochemical Biophysical Research Communications* 211: 74-82, 1995.
75. Essani, N.A., Fisher, M.A., Farhood, A., Manning, A.M., Smith, C.W., and **Jaeschke, H.**: Cytokine-induced hepatic intercellular adhesion molecule-1 (ICAM-1) mRNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. *Hepatology* 21: 1632-1639, 1995.
76. Wang, Y., Mathews, W.R., Guido, D.M., and **Jaeschke, H.**: Inhibition of nitric oxide synthesis aggravates reperfusion injury after hepatic ischemia and endotoxemia. *Shock* 4: 282-288, 1995.

77. Hillesheim, W., **Jaeschke, H.**, and Neumann, H.G.: Cytotoxicity of aromatic amines in rat liver and oxidative stress. *Chemico Biological Interactions* 98: 85-95, 1995.
78. **Jaeschke, H.**, Liu, P., McGuire, G.M., Farhood, A., and Smith, C.W.: Sequential activation of Kupffer cells and neutrophils to generate reactive oxygen contributes to liver injury in endotoxin shock after hepatic ischemia. *In: Cells of the Hepatic Sinusoid*, Vol. 5 (E. Wisse, D.L. Knook, K. Wake; eds), Kupffer Cell Foundation, Leiden, 1995, pp. 14-16.
79. Essani, N.A., Fisher, M.A., Manning, A.M., Farhood, A., and **Jaeschke, H.**: Tumor necrosis factor- α induces hepatic intercellular adhesion molecule-1 (ICAM-1) gene expression in galactosamine-endotoxin shock in mice. *In: Cells of the Hepatic Sinusoid*, Vol. 5 (E. Wisse, D.L. Knook, K. Wake; eds), Kupffer Cell Foundation, Leiden, 1995, pp. 177-179.
80. Liu, P., McGuire, G.M., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Kupffer cells and neutrophils contribute to organ damage during endotoxin shock and acute liver failure. *In: The Immune Consequences of Trauma, Shock and Sepsis- Mechanisms and Therapeutic Approaches*, Vol I (Faist, E., Baue, A.E., Schildberg, F.W., eds.), Pabst S.P., Lengerich, 1996, pp. 953-957.
81. **Jaeschke, H.**, Liu, P., Vonderfecht, S.L., Farhood, A., and Fisher, M.A.: U-74006F (Tirilazad mesylate) protects in a model of endotoxin shock and acute liver failure. *In: The Immune Consequences of Trauma, Shock and Sepsis- Mechanisms and Therapeutic Approaches*, Vol II/2 (Faist, E., Baue, A.E., Schildberg, F.W., eds.), Pabst S.P., Lengerich, 1996, pp. 1275-1279.
82. McGuire, G.M., Liu, P., and **Jaeschke, H.**: Neutrophil-induced lung damage after hepatic ischemia and endotoxemia. *Free Radical Biological Medicine* 20: 189-197, 1996.
83. **Jaeschke, H.**, Essani, N.A., Fisher, M.A., Vonderfecht, S., Farhood, A., and Smith, C.W.: Release of soluble intercellular adhesion molecule-1 (sICAM-1) into bile and blood in murine endotoxin shock. *Hepatology* 23: 530-536, 1996.
84. Essani, N.A., McGuire, G.M., Manning, A.M., and **Jaeschke, H.**: Endotoxin-induced activation of the nuclear transcription factor κ B in hepatocytes, Kupffer cells and endothelial cells *in vivo*. *Journal of Immunology* 156: 2956-2963, 1996.
85. Wang, Y., Mathews, W.R., Guido, D., and **Jaeschke, H.**: The 21-aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation. *Journal of Pharmacology and Experimental Therapeutics* 277: 714-720, 1996.

86. McKenna, R.M., Laskey, R.E., Wang Y., **Jaeschke, H.**, and Mathews, W.R.: Effect of endotoxin enhanced hepatic reperfusion injury on endothelium-dependent relaxation in rat aorta. *Shock* 6: 106-111, 1996.
87. **Jaeschke, H.**, Smith, C.W., Clemens, M.G., Ganey, P.E., and Roth, R.A.: Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxicity of neutrophils (Review). *Toxicology and Applied Pharmacology* 139: 213-226, 1996.
88. **Jaeschke, H.**: Glutathione-dependent defense mechanisms against intracellular and vascular oxidant stress in the liver (Invited Review). *Toxicologic Pathology* 24: 387-388, 1996.
89. **Jaeschke, H.**, Farhood, A., Fisher, M.A., and Smith, C.W.: Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of β_2 integrins and intercellular adhesion molecule-1. *Shock* 6: 351-356, 1996.
90. **Jaeschke, H.**: Chemokines, neutrophils and inflammatory liver injury (Editorial Comment). *Shock* 6: 403-404, 1996.
91. **Jaeschke, H.**: Preservation injury: Mechanisms, prevention and consequences (Invited Review). *Journal of Hepatology* 25: 774-780, 1996.
92. **Jaeschke, H.**: Chemokines and liver inflammation: The battle between pro- and antiinflammatory mediators (Invited Commentary). *Hepatology* 25: 252-253, 1997.
93. Essani, N.A., Fisher, M.A., and **Jaeschke, H.**: Inhibition of NF- κ B activation by dimethyl sulfoxide correlates with suppression of TNF- α formation, reduced ICAM-1 gene transcription and protection against endotoxin-induced liver injury. *Shock* 7: 90-96, 1997.
94. **Jaeschke, H.**: Antioxidant defense mechanisms. In: *Comprehensive Toxicology* (I.G. Sipes, C.A. McQueen, A.J. Gandolfi, eds.), Volume IX: *Hepatic and Gastrointestinal Toxicology* (R.S. McCuskey, D.L. Earnest, eds.), Elsevier, Oxford, 1997, pp. 181-197.
95. Essani, N.A., Fisher, M.A., Farhood, A., and **Jaeschke, H.**: The pathophysiological role of P-selectin gene transcription during endotoxin-induced liver damage. In: Proceedings of the 4th Int. Congress on the Immune Consequences of Trauma, Shock, and Sepsis, E. Faist, ed., Monduzzi Editori, Bologna, Italy, 549-552.
96. Fisher, M.A., Eversole, R.R., Beuving, L.J., and **Jaeschke, H.**: Sinusoidal endothelial cell and parenchymal cell injury during endotoxemia and hepatic ischemia-reperfusion: Protection by the 21-aminosteroid tirilazad mesylate. *International Hepatology Communications* 6: 121-129, 1997.

97. Chosay, J.G., Essani, N.A., Dunn, C.J., and **Jaeschke, H.**: Neutrophil margination and extravasation in sinusoids and venules of the liver during endotoxin-induced injury. *American Journal of Physiology* 272: G1195-G1200, 1997.
98. **Jaeschke, H.** and Smith, C.W.: Mechanisms of neutrophil-induced parenchymal cell injury. (Invited Review) *Journal of Leukocyte Biology* 61: 647-653, 1997.
99. Essani, N.A., Bajt, M.L., Vonderfecht, S.L., Farhood, A., and **Jaeschke, H.**: Transcriptional activation of vascular cell adhesion molecule-1 (VCAM-1) gene *in vivo* and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. *Journal of Immunology*, 158: 5941-5948, 1997.
100. **Jaeschke, H.**: Cellular adhesion molecules: Regulation and role in the pathogenesis of liver disease. (Invited Review) *American Journal of Physiology Gastrointest Liver Physiol* 273: G602-G611, 1997.
101. **Jaeschke, H.**, Essani, N.A., Farhood, A., and Smith, C.W.: Mechanisms of inflammatory liver injury during ischemia-reperfusion and endotoxemia. *In: Cells of the Hepatic Sinusoid*, Vol. 6 (E. Wisse, D.L. Knook, C. Balabaud; eds), Kupffer Cell Foundation, Leiden, pp. 158-163, 1997.
102. Essani, N.A., Bajt, M.L., Manning, A.M., and **Jaeschke, H.**: Activation of nuclear factor- κ B and transcription of adhesion molecule genes during endotoxemia in the liver. *In: Cells of the Hepatic Sinusoid*, Vol. 6 (E. Wisse, D.L. Knook, C. Balabaud; eds), Kupffer Cell Foundation, Leiden, pp. 179-182, 1997.
103. Wang, Y., Fisher, M.A., and **Jaeschke, H.**: Detoxification of Kupffer cell-derived reactive oxygen and reactive nitrogen species by plasma glutathione during hepatic ischemia-reperfusion injury. *In: Cells of the Hepatic Sinusoid*, Vol. 6 (E. Wisse, D.L. Knook, C. Balabaud; eds), Kupffer Cell Foundation, Leiden, pp. 205-206, 1997.
104. **Jaeschke, H.**: Therapeutic strategies directed against Kupffer cells and their products: Clinical implications. (Invited Review) *In: 1997 Postgraduate Course "Liver Injury Update: Clinical Implications and Mechanistic Role of Cells of the Liver"*. Edited by American Association for the Study of Liver Diseases, pp. 229-237, 1997.
105. **Jaeschke, H.**, and Smith, C.W.: Cell adhesion and migration III. Leukocyte adhesion and transmigration in the liver vasculature. (Invited Review) *American Journal of Physiology Gastrointest Liver Physiol* 273: G1169-G1173, 1997.
106. Bell, F.P., Essani, N.A., Manning, A.M., and **Jaeschke, H.**: Ischemia-reperfusion activates the nuclear transcription factor NF- κ B and upregulates messenger RNA synthesis of adhesion molecules in the liver *in vivo*. *Hepatology Research* 8: 178-188, 1997.

107. Essani, N.A., Fisher, M.A., Simmons, C.A., Hoover, J.L., Farhood, A., and **Jaeschke, H.**: Increased P-selectin gene expression in the liver vasculature and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. *Journal of Leukocyte Biology* 63: 288-296, 1998.
108. **Jaeschke, H.**, Fisher, M.A., Lawson, J.A., Simmons, C.A., Farhood, A., and Jones, D.A.: Activation of caspase-3 (CPP32)-like proteases is essential for TNF- α -induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. *Journal of Immunology* 160: 3480-3486, 1998.
109. Chosay, J.G., Fisher, M.A., Farhood, A., Ready, K.A., Dunn, C.J., and **Jaeschke, H.**: Role of PECAM-1 (CD31) for neutrophil transmigration in murine models of liver and peritoneal inflammation. *American Journal of Physiology Gastrointest Liver Physiol* 274: G776-G782, 1998.
110. Wang, Y., Lawson, J.A., and **Jaeschke, H.**: Differential effect of 2-aminoethyl-isothiourea, an inhibitor of the inducible nitric oxide synthase, on microvascular blood flow and organ injury in models of hepatic ischemia-reperfusion injury and endotoxemia. *Shock* 10: 20-25, 1998.
111. Lawson, J.A., Fisher, M.A., Simmons, C.A., Farhood, A., and **Jaeschke, H.**: Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models endotoxin- and Fas-antibody-mediated liver injury. *Hepatology* 28: 761-767, 1998.
112. **Jaeschke, H.**: Mechanism of reperfusion injury after warm ischemia of the liver. (Invited Review) *Journal of Hepatobiliary Pancreatic Surgery* 21: 402-408, 1998.
113. Smith, C.W., Simon, S.I., and **Jaeschke, H.**: Multistep processes in neutrophil homotypic aggregation and tissue injury. In: *Cytokines in Severe Sepsis and Shock*, (H. Redl, G. Schlag, eds.), Birkhauser Verlag AG, Basel, Switzerland, pp. 173-197, 1999.
114. **Jaeschke, H.**, Ho Y.-S., Fisher, M.A., Lawson, J.A., and Farhood, A.: Glutathione peroxidase deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: Importance of an intracellular oxidant stress. *Hepatology* 29: 443-450, 1999.
115. Lawson, J.A., Fisher, M.A., Simmons, C.A., Farhood, A., and **Jaeschke, H.**: Inhibition of Fas receptor (CD95) - induced hepatic caspase activation and apoptosis by acetaminophen in mice. *Toxicology and Applied Pharmacology* 156: 179-186, 1999.
116. Bilzer, M., **Jaeschke, H.**, Vollmar, A.M., Paumgartner, G., and Gerbes, A.L.: Prevention of Kupffer cell-induced injury in rat liver by atrial natriuretic peptide (ANP): A novel endogenous defense mechanism against oxidant injury. *American Journal of Physiology Gastrointest Liver Physiol* 276: G1137-G1144, 1999.

117. **Jaeschke, H.**, Ho, Y.-S., Fisher, M.A., Lawson, J.A., and Farhood, A.: Reactive oxygen and inflammatory liver injury. *In: Cells of the Hepatic Sinusoid*, Vol. 7 (E. Wisse, D.L. Knook, R. Fraser; eds), Kupffer Cell Foundation, Leiden, pp. 211-215, 1999.
118. Bilzer, M., **Jaeschke, H.**, Vollmar, A.M., Paumgartner, G., and Gerbes, A.L.: Atrial natriuretic peptide (ANP) prevents Kupffer cell-induced injury in rat liver. *In: Cells of the Hepatic Sinusoid*, Vol. 7 (E. Wisse, D.L. Knook, R. Fraser; eds), Kupffer Cell Foundation, Leiden, pp. 228-229, 1999.
119. Lawson, J.A., Fisher, M.A., Farhood, A., and **Jaeschke, H.**: Apoptosis versus neutrophil-mediated injury to sinusoidal lining cells in endotoxin shock and anti-Fas antibody-mediated liver injury. *In: Cells of the Hepatic Sinusoid*, Vol. 7 (E. Wisse, D.L. Knook, R. Fraser; eds), Kupffer Cell Foundation, Leiden, pp. 235-236, 1999.
120. **Jaeschke, H.**: Is anti-P-selectin therapy effective in hepatic ischemia-reperfusion injury because it inhibits neutrophil recruitment? (Editorial Comment) *Shock* 12: 233-234, 1999.
121. Rensing, H., Bauer, I., Peters, I., Wein, T., Silomon, M., **Jaeschke, H.**, and Bauer, M.: Role of reactive oxygen species for hepatocellular injury and heme oxygenase-1 gene expression following hemorrhage and resuscitation. *Shock* 12: 300-308, 1999.
122. **Jaeschke, H.**: Kupffer cell-induced oxidant stress during hepatic ischemia-reperfusion: Does the controversy continue? (Invited Editorial Comment). *Hepatology* 30: 1527-1528, 1999.
123. Lawson, J.A., Farhood, A., Hopper, R.D., Bajt, M.L., and **Jaeschke, H.**: The hepatic inflammatory response after acetaminophen overdose: The role of neutrophils. *Toxicological Sciences* 54: 509-516, 2000.
124. **Jaeschke, H.**: Reactive oxygen and mechanisms of inflammatory liver injury (Invited Review). *Journal of Gastroenterology and Hepatology* 15: 718-724, 2000.
125. Bauer, I., Vollmar, B., **Jaeschke, H.**, Rensing, H., Kraemer T., Larsen R., and Bauer, M.: Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat. *Journal of Hepatology* 32: 395-406, 2000.
126. **Jaeschke, H.**: Mechanisms of ischemia-reperfusion injury. *In: Hepatology 2000*, (U. Beuers, A.L. Gerbes, D. Jungst, G.R. Pape, M. Sackmann, T. Sauerbruch, eds.), Kluwer Academic Publishers, Lancaster, UK, pp. 259-269.
127. Bajt, M.L., Lawson, J.A., Vonderfecht, S.L., Gujral, J.S., and **Jaeschke, H.**: Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a

- caspase-8 inhibitor *in vivo*: Evidence for postmitochondrial processing of caspase-8. *Toxicological Sciences* 58: 109-117, 2000.
128. **Jaeschke, H.**, Farhood, A., Cai, S.X., Tseng, B.Y., and Bajt, M.L.: Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. *Toxicology and Applied Pharmacology* 169: 77-83, 2000.
 129. Lawson, J.A., Burns, A.R., Farhood, A., Bajt, M.L., Collins, R.G., Smith, C.W., and **Jaeschke, H.**: Functional importance of E- and L-selectin for neutrophil-induced liver injury during endotoxemia in mice. *Hepatology* 32: 990-998, 2000.
 130. Gujral, J.S., Bucci, T.J., Farhood, A., and **Jaeschke, H.**: Mechanism of cell death during hepatic ischemia-reperfusion in rats: Apoptosis or necrosis? *Hepatology* 33: 397-405, 2001.
 131. **Jaeschke, H.**: Reactive oxygen and neutrophil-induced liver injury. *In: Oxidative Stress and Digestive Diseases*, (Yoshikawa, T., ed.), Karger AG, Basel, pp. 13-23, 2001.
 132. Knight, T.R., Kurtz, A., Bajt, M.L., Hinson, J.A., and **Jaeschke, H.**: Vascular and hepatocellular peroxynitrite formation during acetaminophen-induced liver injury: Role of mitochondrial oxidant stress. *Toxicological Sciences* 62: 212-220, 2001.
 133. **Jaeschke, H.**, and Fisher, M.A.: Activation and priming of Kupffer cells for reactive oxygen formation after hemorrhagic shock and resuscitation in rats. *In: Cells of the Hepatic Sinusoid*, Vol. 8 (E. Wisse, M. Arthur, R.B. De Zanger, D.L. Knook; eds), Kupffer Cell Foundation, Leiden, pp.57-58, 2001.
 134. **Jaeschke, H.**, Farhood, A., and Bajt, M.L.: Importance of CXC chemokines in neutrophil activation and recruitment into hepatic sinusoids during endotoxemia. *In: Cells of the Hepatic Sinusoid*, Vol. 8 (E. Wisse, M. Arthur, R.B. De Zanger, D.L. Knook; eds), Kupffer Cell Foundation, Leiden, pp. 47-50, 2001.
 135. **Jaeschke, H.**: Neutrophils and liver transplantation. *In: Cells of the Hepatic Sinusoid*, Vol. 8 (E. Wisse, M. Arthur, R.B. De Zanger, D.L. Knook; eds), Kupffer Cell Foundation, Leiden, pp. 308-313, 2001.
 136. **Jaeschke, H.** Cellular mechanisms of hepatic ischemia-reperfusion injury. *In: 7th World Congress for Microcirculation*, Monduzzi Editori, Bologna, Italy, pp. 77 – 84, 2001.
 137. Bajt, M.L., Vonderfecht, S.L., and **Jaeschke, H.**: Differential protection with inhibitors of caspase-8 and caspase-3 in murine models of TNF and Fas receptor-mediated hepatocellular apoptosis. *Toxicology and Applied Pharmacology* 175: 243-252, 2001.

138. Rensing, H., **Jaeschke, H.**, Bauer, I., Patau, C., Datene, V., Pannen, B.H.J., and Bauer, M.: Differential activation pattern of redox-sensitive transcription factors and stress-inducible dilator systems HO-1 and iNOS in hemorrhagic and endotoxin shock. *Critical Care Medicine* 29: 1962-1971, 2001.
139. Bajt, M.L., Farhood, A., and **Jaeschke, H.**: Effects of CXC chemokines on neutrophil activation and sequestration in the hepatic vasculature. *American Journal of Physiology Gastrointest Liver Physiol* 281: G1188-G1195, 2001.
140. **Jaeschke, H.**, Gores, G.J., Cederbaum, A.I., Hinson, J.A., Pessayre, D., and Lemasters, J.J.: Mechanisms of hepatotoxicity (Review). *Toxicological Sciences* 65: 166-176, 2002.
141. **Jaeschke, H.**: Oxidative stress, antioxidant defense and liver injury. *In: Drug-induced Liver Disease*, (Kaplowitz, N., and DeLeve, L.D., eds.), Marcel Dekker, Inc., New York, pp. 35-54, 2002.
142. **Jaeschke, H.**: Inflammation in response to hepatocellular apoptosis. (Editorial Comment). *Hepatology* 35: 964-966, 2002.
143. **Jaeschke, H.**: Neutrophil-mediated tissue injury in alcoholic hepatitis (Invited Review). *Alcohol* 27: 23-27, 2002.
144. Gujral, J.S., Knight, T.R., Farhood, A., Bajt, M.L., and **Jaeschke, H.**: Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? *Toxicological Sciences* 67: 322-328, 2002.
145. Knight, T.R., and **Jaeschke, H.**: Acetaminophen-induced inhibition of Fas receptor-mediated liver cell apoptosis: mitochondrial dysfunction versus glutathione depletion. *Toxicology and Applied Pharmacology* 181: 133-141, 2002.
146. **Jaeschke, H.**: Antioxidant gene therapy and hepatic ischemia-reperfusion injury. (Editorial Comment). *Hepatology* 36: 243-245, 2002.
147. **Jaeschke, H.**, and Farhood, A.: Kupffer cell activation after no-flow ischemia versus hemorrhagic shock. *Free Radical Biology and Medicine* 33: 210-219, 2002.
148. **Jaeschke, H.**: Xanthine oxidase-induced oxidant stress during hepatic ischemia-reperfusion: are we coming full circle after 20 years? (Invited Editorial) *Hepatology* 36: 761-763, 2002.
149. **Jaeschke, H.** Redox considerations in hepatic injury and inflammation (Forum Editorial). *Antioxidants and Redox Signaling* 4: 699-700, 2002.
150. Bajt, M.L., Ho, Y.-S., Vonderfecht, S.L., and **Jaeschke, H.**: Reactive oxygen as modulator of TNF and Fas receptor-mediated apoptosis *in vivo*: Studies with

- glutathione peroxidase-deficient mice. *Antioxidants and Redox Signaling* 4: 733-740, 2002.
151. **Jaeschke, H.** Reperfusion injury after warm ischemia or cold storage of the liver: role of apoptotic cell death. *Transplantation Proceedings* 34: 2656-2658, 2002.
 152. Knight, T.R., Ho, Y.-S., Farhood, A., and **Jaeschke, H.**: Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione. *Journal of Pharmacology and Experimental Therapeutics* 303: 468-475, 2002.
 153. **Jaeschke, H.**: Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. (Invited Review). *American Journal of Physiology Gastrointest Liver Physiol* 284: G15-G26, 2003.
 154. **Jaeschke, H.**: Anti-selectin therapy against hepatic ischemia-reperfusion injury? (Editorial Comment). *Hepatology* 37: 220-222, 2003.
 155. **Jaeschke, H.**: Involvement of Kupffer cells in the interactions between neutrophils and sinusoidal endothelial cells in rats. (Letter). *Shock* 19: 394-395, 2003.
 156. **Jaeschke, H.**, and Bajt, M.L.: Regulation of apoptotic signaling pathways in hepatocytes *in vivo*. (Editorial Comment). *Hepatology* 37: 942-945, 2003.
 157. Paxian, M., Bauer, I., Rensing, H., **Jaeschke, H.**, Mautes, A.E.M., Kolb, S.A., Wolf, B., Stockhausen, A., Jeblick, S., and Bauer, M.: Recovery of hepatocellular ATP and pericentral apoptosis after hemorrhage and resuscitation. *FASEB Journal* 17: 993-1002, 2003.
 158. **Jaeschke, H.**: Role of reactive oxygen species in hepatic ischemia-reperfusion injury and preconditioning. (Invited Review). *Journal of Investigative Surgery* 16: 127-140, 2003.
 159. Gujral, J.S., Farhood, A., and **Jaeschke, H.**: Oncotic necrosis and caspase-dependent apoptosis during galactosamine-induced liver injury in rats. *Toxicology and Applied Pharmacology* 190: 37-46, 2003.
 160. Gujral, J.S., Farhood, A., Bajt, M.L., and **Jaeschke, H.**: Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. *Hepatology* 38: 355-363, 2003.
 161. **Jaeschke, H.**, Knight, T.R., and Bajt, M.L.: The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity (Review). *Toxicology Letters* 144: 279-288, 2003.

162. Li, C., Liu, J., Waalkes, M.P., and **Jaeschke, H.**: Gene array analysis of the hepatic response to endotoxin in glutathione peroxidase-deficient mice. *Toxicology Letters* 144: 397-406, 2003.
163. **Jaeschke, H.** and Lemasters, J.J.: Apoptosis versus oncotic necrosis in hepatic ischemia-reperfusion injury (Invited Review). *Gastroenterology* 125: 1246-1257, 2003.
164. Bajt, M.L., Knight, T.R., Farhood, A., and **Jaeschke, H.**: Scavenging peroxynitrite with glutathione promotes regeneration and enhances survival during acetaminophen-induced liver injury in mice. *Journal of Pharmacology and Experimental Therapeutics* 307: 67-73, 2003.
165. **Jaeschke, H.**: Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity? (Editorial Commentary). *Hepatology* 38: 1054-1056, 2003.
166. Knight, T.R., Farriss, M.W., Farhood, A., and **Jaeschke, H.**: Role of lipid peroxidation as mechanism of liver injury after acetaminophen overdose in mice. *Toxicological Sciences* 76: 229-236, 2003.
167. James, L.P., McCullough, S.S., Knight, T.R., **Jaeschke, H.**, and Hinson, J.A.: Acetaminophen toxicity in mice lacking NADPH oxidase activity: role of peroxynitrite formation and mitochondrial oxidant stress. *Free Radical Research* 37: 1289-1297, 2003.
168. Dorman, R.B., Bajt, M.L., Farhood, A., Mayes, J., and **Jaeschke, H.**: Heme oxygenase-1 (HO-1) induction in hepatocytes and non-parenchymal cells protects against liver injury during endotoxemia. *Comparative Hepatology* 2 (Suppl 1): S42, 2004.
169. Knight, T.R., and **Jaeschke, H.**: Peroxynitrite formation and sinusoidal endothelial cell injury during acetaminophen hepatotoxicity in mice. *Comparative Hepatology* 2 (Suppl 1): S46, 2004.
170. Gujral, J.S., Hinson, J.A., and **Jaeschke, H.**: Chlorotyrosine protein adducts are reliable biomarkers of neutrophil-induced hepatotoxicity *in vivo*. *Comparative Hepatology* 2 (Suppl 1): S48, 2004.
171. **Jaeschke, H.**, and McCuskey, R.S.: The importance of leptin in mice and man (Invited Commentary). *Journal of Hepatology* 40: 359-361, 2004.
172. Gujral, J.S., Liu, J., Farhood, A., Hinson, J.A., and **Jaeschke, H.**: Functional importance of intercellular adhesion molecule-1 in the mechanism of neutrophil-induced liver injury during obstructive cholestasis in mice. *American Journal of Physiology Gastrointest Liver Physiol* 286: G499-G507, 2004.

173. **Jaeschke, H.**, Gujral, J.S., and Bajt, M.L.: Apoptotic and oncotoc necrosis in liver disease (Invited Review). *Liver International* 24: 85-89, 2004.
174. Gujral, J.S., Hinson, J.A., Farhood, A., and **Jaeschke, H.**: NADPH oxidase-derived oxidant stress is critical for neutrophil-induced cytotoxicity during endotoxemia. *American Journal of Physiology Gastrointest Liver Physiol* 287: G243-G252, 2004.
175. Bajt, M.L., Knight, T.R., Lemasters, J.J., and **Jaeschke, H.**: Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes: protection by *N*-acetyl cysteine. *Toxicological Sciences* 80: 343 - 349, 2004.
176. Gujral, J.S., Liu, J., Farhood, A., and **Jaeschke, H.**: Reduced oncotoc necrosis in Fas receptor deficient C57BL/6J-*lpr* mice after bile duct ligation. *Hepatology* 40: 998-1007, 2004.
177. Kon, K., Kim, J.S., **Jaeschke, H.**, and Lemasters, J.J.: Mitochondrial permeability transition in acetaminophen-induced necrotic and apoptotic cell death to cultured mouse hepatocytes. *Hepatology* 40: 1170-1179, 2004.
178. **Jaeschke, H.**, and Bajt, M.L.: Critical role of CXC chemokines in endotoxemic liver injury in mice. *Journal of Leukocyte Biology (Letter)* 76: 1089-1090, 2004.
179. Dorman, R., Gujral, J.S., Bajt, M.L., Farhood, A., and **Jaeschke, H.**: Generation and functional significance of CXC chemokine formation for neutrophil-induced liver injury during endotoxemia. *American Journal of Physiology Gastrointest Liver Physiol* 288: G880-G886, 2005.
180. Cover, C., Fickert, P., Knight, T.R., Fuchsbichler, A., Farhood, A., Trauner, M., and **Jaeschke, H.**: Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell necrosis in mice. *Toxicological Sciences* 84: 201-208, 2005.
181. **Jaeschke, H.**, Cover, C., Bajt, M.L. Inflammation and drug hepatotoxicity: aggravation of injury or clean-up mission? (Editorial Comment). *Hepatology* 41: 1176-1178, 2005.
182. **Jaeschke, H.**: Comments on "Glycogen synthase kinase-3 mediates acetaminophen-induced apoptosis in human hepatoma cells" (Letter). *Journal of Pharmacology and Experimental Therapeutics* 314: 1401-1402, 2005.
183. Hasegawa, T., Malle, E., Farhood, A., and **Jaeschke, H.**: Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning. *American Journal of Physiology Gastrointest Liver Physiol* 289: 760-767, 2005.

184. **Jaeschke, H.:** Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity (Invited Review). *Expert Opinions on Drug Metabolism and Toxicology*, 1: 389-397, 2005.
185. Cover, C., Mansouri, A., Knight, T.R., Bajt, M.L., Lemasters, J.J., Pessayre, D., and **Jaeschke, H.:** Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. *Journal of Pharmacology and Experimental Therapeutics* 315: 879-887, 2005.
186. **Jaeschke, H.,** and Bajt, M.L.: Intracellular signaling mechanisms of acetaminophen-induced liver cell death. (Invited Review) *Toxicological Sciences* 89: 31-41, 2006.
187. **Jaeschke, H.,** Cover, C., and Bajt, M.L.: Role of caspases in acetaminophen-induced liver injury. *Life Sciences* 78: 1670-1676, 2006.
188. Fickert, P., Fuchsbichler, A., Marschall, H.U., Wagner, M., Zollner, G., Krause, R., Zatloukal, K., **Jaeschke, H.,** Denk, H., and Trauner, M.: Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. *American Journal of Pathology* 168: 410-422, 2006.
189. Fickert, P., Wagner, M., Marschall, H.U., Fuchsbichler, A., Zollner, G., Tsybrovskyy O., Zatloukal, K., Liu, J., Waalkes, M.P., Cover, C., Denk, D., Hofmann, A.F., **Jaeschke, H.,** and Trauner, M.: 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in *Mdr2 (Abcb4)* knockout mice. *Gastroenterology* 130: 465-481, 2006.
190. **Jaeschke, H.:** Mechanisms of neutrophil-mediated liver cell injury during ischemia-reperfusion and other acute inflammatory conditions. (Invited Review). *American Journal of Physiology Gastrointestinal and Liver Physiology* 290: G1083-G1088, 2006.
191. **Jaeschke, H.:** How relevant are neutrophils for acetaminophen hepatotoxicity? (Invited Editorial Comment). *Hepatology* 43: 1191-1194, 2006.
192. **Jaeschke, H.:** Mechanisms of liver cell destruction (Invited Review). In *Zakim and Boyer's Hepatology*, 5th edition. (Boyer, T.D., Wright, T.L., Manns, M., eds); Saunders, Elsevier, 2006; pp. 37-51.
193. Ito, Y., Abril, E.R., Bethea, N.W., McCuskey, M.K., Cover, C., **Jaeschke, H.,** and McCuskey, R.S.: Mechanisms and pathophysiological implications of sinusoidal endothelial cell gap formation following treatment with galactosamine/endotoxin in mice. *American Journal of Physiology Gastrointestinal and Liver Physiology* 291: G211-G218, 2006.
194. **Jaeschke, H.,** and Hasegawa, T.: Role of neutrophils in acute inflammatory liver injury. (Invited Review). *Liver International* 26: 912-919, 2006.

195. Cover, C., Liu, J., Farhood, A., Malle, E., Waalkes, M.P., Bajt, M.L., and **Jaeschke, H.**: Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. *Toxicology and Applied Pharmacology* 216: 98-107, 2006.
196. Bajt, M.L., Cover, C., Lemasters, J.J., and **Jaeschke, H.**: Nuclear translocation of endonuclease G and apoptosis-inducing factor during acetaminophen-induced liver injury. *Toxicological Sciences* 94: 217-225, 2006.
197. Hasegawa, T., Ito, Y., McCuskey, R.S., and **Jaeschke, H.**: Molecular mechanisms of ischemia-reperfusion injury in steatotic livers. In: *Minophagen Medical Review*, Supplement 35 (McCuskey, R.S. and Wake, K., eds.), Minophagen Pharmaceutical Co., Ltd. pp. 64-67, 2007.
198. **Jaeschke, H.**: Troglitazone hepatotoxicity: Are we getting closer to understanding the pathophysiology of idiosyncratic liver injury? (Invited Commentary) *Toxicological Sciences* 97: 1-3, 2007.
199. **Jaeschke, H.**: Kupffer Cells. (Invited Review) In "Textbook of Hepatology: From Basic Science to Clinical Practice, 3rd edition". (Rodes, J., Benhamou, J.P., Blei, A.T., Reichen, J., Rizzetto, M., eds.) Blackwell Publishing, pp.36-42, 2007.
200. **Jaeschke, H.**, and Liu, J.: Neutrophil depletion protects against murine acetaminophen hepatotoxicity: Another perspective. (Letter). *Hepatology* 45: 1588-1589, 2007.
201. Hasegawa, T., Ito, Y., Wijeweera, J., Liu, J., Malle, E., Farhood, A., McCuskey, R.S., and **Jaeschke, H.**: Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice. *American Journal of Physiology Gastrointestinal and Liver Physiology* 292: G1385-G1395, 2007.
202. Fickert, P., Stöger, U., Fuchsbichler, A., Moustafa, T., Marschall, H.-U., Weiglein A.H., Tsybrovskyy, O., **Jaeschke, H.**, Zatloukal K., Denk, H., and Trauner, M.: A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. *American Journal of Pathology* 171: 525-536, 2007.
203. Ramaiah, S.K., and **Jaeschke, H.**: Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury (Invited Review). *Toxicology Mechanisms and Methods* 17: 431-440, 2007.
204. Wagner, M., Zollner, G., Fickert, P., Gumhold, J., Silbert, D., Fuchsbichler, A., Gujral, J.S., Zatloukal, K., Denk, H., **Jaeschke, H.**, and Trauner, M.: Hepatobiliary transporter expression in ICAM^{-/-} and *lpr* mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. *Drug Metabolism & Disposition* 35: 1694-1699, 2007.

205. Ramaiah, S.K., and **Jaeschke, H.**: Role of neutrophils in the pathogenesis of acute inflammatory liver injury (Invited Review). *Toxicologic Pathology* 35: 757-766, 2007.
206. **Jaeschke, H.**: Toxic Responses of the Liver. (Invited Review). *In: Casarett and Doull's Toxicology*, 7th edition; (Klaassen, C.D., ed.) McGraw Hill Publ., pp. 557-582, 2007.
207. **Jaeschke, H.**: Antioxidant Defense in Liver Injury: Oxidative Stress, Antioxidant Defense and Liver Injury. *In: Drug-induced Liver Disease*, 2nd edition; (Kaplowitz, N., and DeLeve, L.D., eds.), Marcel Dekker, Inc., New York, pp. 33-48, 2007.
208. Bajt, M.L., Farhood, A., Lemasters, J.J., and **Jaeschke, H.**: Mitochondrial Bax translocation accelerates DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity. *Journal of Pharmacology & Experimental Therapeutics* 324: 8-14, 2008.
209. Andringa, K.K., Bajt, M.L., **Jaeschke, H.**, and Bailey, S.M.: Mitochondrial protein thiol modifications in acetaminophen hepatotoxicity: effect on HMG-CoA synthase. *Toxicology Letters* 177: 188-197, 2008.
210. **Jaeschke, H.** and Hong, J.Y.: Apoptosis and oncotic necrosis: profibrotic signalling mechanisms of cell death. *In: Liver Cirrhosis: From Pathophysiology to Disease Management (Falk Symposium 162)*; (Bosch, J., Burroughs, A.K., Lammert, F., Lebec, D., Sauerbruch, T., eds.), Springer Verlag, Berlin, pp. 3-10, 2008.
211. Bajt, M.L., Yan, H.-M., Farhood, A., and **Jaeschke, H.**: Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. *Toxicological Sciences* 104: 419-427, 2008.
212. **Jaeschke, H.**: Innate immunity and acetaminophen-induced liver injury: why so many controversies? (Invited Editorial Comment). *Hepatology* 48: 699-701, 2008.
213. Uchiyama, A., Kim, J.S., Kon, K., **Jaeschke, H.**, Ikejima, K., Watanabe, S., and Lemasters, J.J.: Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. *Hepatology* 48: 1644-1654, 2008.
214. Hong, J.Y., Lebofsky, M., Farhood, A., and **Jaeschke, H.**: Oxidant stress-induced liver injury *in vivo*: role of apoptosis, oncotic necrosis and JNK activation. *American Journal of Physiology Gastrointestinal and Liver Physiology* 296: G572-G581, 2009.
215. Smedsrod, B., LeCouteur, D., Ikejima, K., **Jaeschke, H.**, Kawada, N., Naito, M., Knolle, P., Nagy, L., Senoo, H., Vidal-Vanaclocha, V., Yamaguchi, N.: Hepatic sinusoidal cells in health and disease: Update from the 14th International Symposium. *Liver International* 29: 490-501, 2009.

216. **Jaeschke, H.:** Reactive oxygen species, hypohalites, and reactive nitrogen species in liver pathophysiology. In: *Endogenous Toxins: Diet, Genetics, Disease and Treatment* (O'Brien, P.J., Bruce, W.R., eds.) Wiley-VCH Verlag, pp. 249-266, 2009.
217. Nalapareddy, P., Schüngel, S., Hong, J.Y., Manns, M.P., **Jaeschke, H.**, and Vogel, A.: The BH3-only protein Bid does not mediate death-receptor-induced liver injury in obstructive cholestasis. *American Journal of Pathology* 175: 1077-1085, 2009.
218. Schüngel, S., Buitrago-Molina, L.E., Devi, P., Lebofsky, M., Manns, M.P., **Jaeschke, H.**, Gross, A., and Vogel, A.: The strength of the Fas ligand signal determines whether hepatocytes act as type I or type II cells in murine livers. *Hepatology* 50: 1558-1566, 2009.
219. Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., Carrasco, G., Caligiuri, A., Sombetzki, M., Reisinger, E., Tsybrovskyy, O., Zatloukal, K., Denk, H., **Jaeschke, H.**, Pinzani, M., and Trauner, M.: Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *American Journal of Pathology* 175: 2392-2405, 2009.
220. Lemasters, J.J., Uchiyama, A., Kim, J.S., Kon, K., and **Jaeschke, H.:** Role of intracellular iron movement and oxidant stress in hepatocellular injury. In: *The Liver. Biology and Pathobiology, 5th edition*, I.M. Arias, H.J. Alter, J.L. Boyer, D.E. Cohen, N. Fausto, D.A. Shafritz, and A.W. Wolkoff (Eds.), Wiley-Blackwell, Chichester, West-Sussex, UK, pp. 511-520, 2009.
221. Saito, C., Yan, H.M., Artigues, A., Vittal, M.T., Farhood, A., and **Jaeschke, H.:** Mechanism of protection by metallothionein against acetaminophen hepatotoxicity. *Toxicology and Applied Pharmacology* 242: 182-190, 2010.
222. Saito, C., Zwingmann, C., **Jaeschke, H.:** Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and *N*-acetylcysteine. *Hepatology* 51: 246-254, 2010.
223. **Jaeschke, H.:** DAMPen danger signals: Novel therapeutic strategies against post-ischemic inflammation (*Invited Editorial*). *Critical Care Medicine* 38: 998-999, 2010.
224. Copple, B.L., **Jaeschke, H.**, and Klaassen, C.D.: Oxidative stress and the pathogenesis of cholestasis (*Invited Review*). *Seminars in Liver Disease* 30: 195-204, 2010.
225. **Jaeschke, H.**, Williams, C.D., McGill, M.R., and Farhood, A.: Herbal extracts as hepatoprotectants against acetaminophen hepatotoxicity. *World Journal of Gastroenterology* 16: 2448-2450, 2010.
226. Fickert, P., Thueringer, A., Moustafa, T., Silbert, D., Gumhold, J., Tsybrovskyy, O., Lebofsky, M., **Jaeschke, H.**, Denk, H., and Trauner, M.: Role of osteopontin and

- tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. *Laboratory Investigation* 90: 844-852, 2010.
227. Adams, D.H., Ju, C., Ramaiah, S., Uetrecht, J.P. and **Jaeschke, H.**: Mechanisms of immune-mediated liver injury (Review). *Toxicological Sciences* 115: 307-321, 2010.
228. Saito, C., Lemasters, J.J., and **Jaeschke, H.**: c-Jun-N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity. *Toxicology and Applied Pharmacology* 246: 8-17, 2010.
229. **Jaeschke, H.** and Bajt, M.L.: Mechanisms of Acetaminophen Hepatotoxicity. In: C.A. McQueen, ed.; *Comprehensive Toxicology*, volume 9, Oxford: Academic Press, pp. 457-473, 2010.
230. **Jaeschke, H.**: Antioxidant Defense Mechanisms. In: C.A. McQueen, ed.; *Comprehensive Toxicology*, volume 9, Oxford: Academic Press, pp. 319-337, 2010.
231. Kon, K., Kim, J.S., Uchiyama, A., **Jaeschke, H.**, and Lemasters, J.J.: Lysosomal iron mobilization and induction of the mitochondrial permeability transition in acetaminophen-induced toxicity to mouse hepatocytes. *Toxicological Sciences* 117: 101-108, 2010.
232. Williams, C.D., Farhood, A., and **Jaeschke, H.**: Role of caspase-1 and interleukin-1 β in acetaminophen-induced hepatic inflammation and liver injury. *Toxicology and Applied Pharmacology* 247: 169-178, 2010.
233. Williams, C.D., Bajt, M.L., Farhood, A., and **Jaeschke, H.**: Acetaminophen-induced hepatic neutrophil recruitment and liver injury in CD18-deficient mice. *Liver International* 30: 1280-1292, 2010.
234. Yan, H.M., Ramachandran, A., Bajt, M.L., Lemasters, J.J., and **Jaeschke, H.**: The oxygen tension modulates acetaminophen-induced mitochondrial oxidant stress and cell injury in primary cultured hepatocytes. *Toxicological Sciences* 117: 515-523, 2010.
235. **Jaeschke, H.**, Yan, H.M., and Ramachandran, A.: Reactive nitrogen species in acetaminophen-induced mitochondrial damage and toxicity in mouse hepatocytes – a cautionary note on the impact of cell culture conditions. (Letter). *Chemical Research in Toxicology* 23: 1853-1854, 2010.
236. **Jaeschke, H.**: Toxicant-induced liver injury. In: *Molecular Pathology of Liver Diseases* (S.P. Monga, ed), Springer Verlag, Berlin, pp. 641-653, 2011.
237. Allen, K., **Jaeschke, H.**, and Copple, B.L.: Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. *American Journal of Pathology* 178: 175-186, 2011.

238. **Jaeschke, H.:** Reactive oxygen and mechanisms of inflammatory liver injury: present concepts (Invited Review). *Journal of Gastroenterology and Hepatology* **26** (Suppl. 1): 173-179, 2011.
239. Ramachandran, A., Lebofsky, M., Baines, C., Lemasters, J.J., and **Jaeschke, H.:** Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. *Free Radical Research* **45**: 156-164, 2011.
240. **Jaeschke, H.,** Williams, C.D., and Farhood, A.: No evidence for caspase-dependent apoptosis in acetaminophen hepatotoxicity (Letter). *Hepatology* **53**: 718-719, 2011.
241. Luyendyk, J.P., Flanagan, K.C., Williams, C.D., **Jaeschke, H.,** Slusser, J.G., Mackman, N., and Cantor, G.H.: Tissue factor contributes to neutrophil CD11b expression in alpha-naphthylisothiocyanate-treated mice. *Toxicology and Applied Pharmacology* **250**: 256-262, 2011.
242. Ramachandran, A., Lebofsky, M., Weinman, S.A., and **Jaeschke, H.:** Effect of partial manganese superoxide dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity. *Toxicology and Applied Pharmacology* **251**: 226-233, 2011.
243. McGill, M.R., Yan, H.M., Ramachandran, A., Murray, G.J., Rollins, D., and **Jaeschke, H.:** HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. *Hepatology* **53**: 974-982, 2011.
244. Williams, C.D. and **Jaeschke, H.:** Liver toxicology. (Invited Review) In: *Encyclopedia of Environmental Health* (J. Nriagu, ed.), Volume 3, Burlington: Elsevier, pp. 509-514, 2011.
245. **Jaeschke, H.,** McGill, M.R., Williams, C.D., and Ramachandran, A.: Acetaminophen hepatotoxicity – a clinically relevant model to test the efficacy of natural products (Invited Review). *Life Sciences* **88**: 737-745, 2011.
246. Williams, C.D., Antoine, D.J., Shaw, P.J., Benson, C., Farhood, A., Williams, D.P., Kanneganti, T.D., Park, B.K., **Jaeschke, H.:** Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. *Toxicology and Applied Pharmacology* **252**: 289-297, 2011.
247. **Jaeschke, H.,** McGill, M.R., Ramachandran, A. Pathophysiological relevance of proteomics investigations of drug-induced hepatotoxicity in HepG2 cells (Letter). *Toxicological Sciences* **121**: 428-430, 2011.
248. DeLeve, L.D., **Jaeschke, H.,** Kalra, V.K., Asahina, K., Brenner, D.A., and Tsukamoto, H.: Meeting Report - 15th International Symposium on Cells of the Hepatic Sinusoid, 2010. *Liver International* **31**: 762-772, 2011.

249. **Jaeschke, H.**, and Ramachandran, A.: *Hepatology Snapshot*: Reactive oxygen species in the normal and acutely injured liver (Invited Review). *Journal of Hepatology* **55**: 227-228, 2011.
250. Bajt, M.L., Ramachandran, A., Lebofsky, M., Yan, H.M., Farhood, A., Lemasters, J.J., and **Jaeschke, H.**: Apoptosis-inducing factor modulates mitochondrial oxidant stress in acetaminophen hepatotoxicity. *Toxicological Sciences* **122**: 598-605, 2011.
251. Williams, C.D., Koerner, M.R., Lampe, J.N., Farhood, A., and **Jaeschke, H.**: Mouse strain-dependent transient caspase activation during acetaminophen hepatotoxicity does not result in apoptosis or modulation of inflammation. *Toxicology and Applied Pharmacology* **257**: 449-458, 2011.
252. **Jaeschke, H.** and Williams, C.D.: Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury (letter). *Journal of Immunology* **187**: 6168, 2011.
253. **Jaeschke, H.**, Williams, C.D., Ramachandran, A., and Bajt, M.L.: Acetaminophen hepatotoxicity and repair: role of sterile inflammation and innate immunity (Invited Review). *Liver International* **32**: 8-20, 2012.
254. Zhang Y., Hong, J.Y., Rockwell, C.E., Copple, B.L., **Jaeschke, H.**, and Klaassen, C.D. Effect of bile duct ligation on bile acid composition in mouse serum and liver. *Liver International* **32**: 58-69, 2012.
255. Ni, H.M., Bockus, A., **Jaeschke, H.**, and Ding, W.X.: Activation of autophagy protects against acetaminophen hepatotoxicity in mice. *Hepatology* **55**: 222-231, 2012.
256. **Jaeschke, H.**, McGill, M.R., and Ramachandran, A.: Oxidant stress, mitochondria and intracellular cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity (Invited Review). *Drug Metabolism Reviews* **44**: 88-106, 2012.
257. Ni, H.M., **Jaeschke, H.**, and Ding, W.X.: Targeting autophagy for drug-induced hepatotoxicity (Invited Commentary). *Autophagy* **8**: 709-710, 2012.
258. **Jaeschke, H.**, and Woolbright, B.L.: Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. (Invited Review) *Transplantation Reviews* **26**: 103-114, 2012.
259. **Jaeschke, H.**: Therapeutic strategies against ischemia-reperfusion injury: Stem cell therapy and beyond (Invited Commentary). *Critical Care Medicine* **40**: 1381-1382, 2012.

260. McGill, M.R., Sharpe, M.R., Williams, C.D., Taha, M., Curry, S.C., and **Jaeschke, H.**: Mechanisms of acetaminophen hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. *Journal of Clinical Investigation* 122: 1574-1583, 2012.
261. Antoine, D.J., Jenkins, R.E., Dear, J.W., Williams, D.P., McGill, M.R., Sharpe, M.R., Craig, D.G., Simpson, K.J., **Jaeschke, H.**, and Park, B.K.: Molecular forms of HMGB1 and Keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. *Journal of Hepatology* 56: 1070-1079, 2012.
262. Kong, B., Csanaky, I.L., Aleksunes, L.M., Patni, M., Chen, Q., Ma, X. **Jaeschke, H.**, Weir, S., Broward, M., Klaassen, C.D., Guo, G.L.: Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity. *Toxicology and Applied Pharmacology* 261: 189-195, 2012.
263. Ni, H.M., Boggess, N., McGill, M.R., Lebofsky, M., Borude, P., Apte, U., **Jaeschke, H.**, and Ding, W.X.: Liver specific loss of Atg5 causes persistent activation of Nrf2 and protects against acetaminophen-induced liver injury. *Toxicological Sciences* 127: 438-450, 2012.
264. **Jaeschke, H.**, and Ding, W.X.: Autophagy and acetaminophen hepatotoxicity: How useful are Atg7-deficient mice? (Letter). *Journal of Gastroenterology* 47: 845-846, 2012.
265. Aubert, J., Begriche, K., Delannoy, D., Morel, I., Pajaud, J., Ribault, C., Lepage, S., McGill, M.R., Lucas-Clerc, C., Turlin, B., Robin, M.A., **Jaeschke, H.**, and Fromenty, B.: Early acetaminophen hepatotoxicity in obese and diabetic mice is not related to the degree of fatty liver. *Journal of Pharmacology and Experimental Therapeutics* 342: 676-687, 2012.
266. Woolbright, B.L., and **Jaeschke, H.**: Novel insight into the mechanisms of cholestatic liver injury (Invited Review). *World Journal of Gastroenterology* 18: 4985-4993, 2012.
267. Williams, C.D., and Jaeschke, H.: Role of the innate and adaptive immunity during drug-induced liver injury (Invited Review). *Toxicology Research* 1: 161-170, 2012.
268. McGill, M.R., Williams, C.D., Xie, Y., Ramachandran, A., and **Jaeschke, H.**: Acetaminophen-induced liver injury in rats and mice: Comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. *Toxicology and Applied Pharmacology* 264: 387-394, 2012.
269. **Jaeschke, H.**, Williams, C.D., and McGill, M.R.: Caveats of using acetaminophen hepatotoxicity models for natural product testing (Letter). *Toxicology Letters* 215: 40-41, 2012.

270. Woolbright, B.L., Ramachandran, A., McGill, M.R., Yan, H.M., Bajt, M.L., Sharpe, M.R., Lemasters, J.J., and **Jaeschke, H.**: Lysosomal instability and cathepsin B release during acetaminophen hepatotoxicity. *Basic & Clinical Pharmacology and Toxicology* 111: 417-425, 2012.
271. Ding, W.X., Guo, F., Ni, H.M., Bockus, A., Manley, S., Xie, T., Johnson, T., Stolz, D.B., Eskelinen E.-L., **Jaeschke, H.**, and Yin, X.M.: Parkin and Mitofusins reciprocally regulate mitophagy and mitochondrial spheroid formation. *Journal of Biological Chemistry* 287: 42379-42388, 2012.
272. McGill, M.R., and **Jaeschke, H.**: Oxidative Stress, antioxidant defense and liver injury. (Invited Review). In: Drug-induced Liver Disease, 3rd edition; (Kaplowitz, N., and DeLeve, L.D., eds.), Elsevier, pp. 71-84, 2013.
273. Xie, Y., Williams, C.D., McGill, M.R., Lebofsky, M., Ramachandran, A., and **Jaeschke, H.**: Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting P450 isoenzymes but not inflammasome activation. *Toxicological Sciences* 131: 325-335, 2013.
274. **Jaeschke, H.**, McGill, M.R. and Williams, C.D.: The pathophysiological relevance of neutrophils in acetaminophen hepatotoxicity (Letter). *Hepatology* 57: 419, 2013.
275. **Jaeschke, H.**, Williams, C.D., McGill, M.R., Xie, Y., and Ramachandran, A.: Models of drug-induced liver injury for evaluation of phytotherapeutics and other natural products (Review). *Food and Chemical Toxicology* 55: 279-289, 2013.
276. Woolbright, B.L., and **Jaeschke, H.**: Heme oxygenase-1 and platelets in hepatic ischemia reperfusion injury (Invited Editorial). *Journal of Gastroenterology and Hepatology*, 28: 756-757, 2013.
277. McGill, M.R., Lebofsky, M., Norris, H.R., Slawson, M.H., Bajt, M.L., Xie, Y., Williams, C.D., Wilkins, D.G., Rollins, D.E., and **Jaeschke, H.**: Plasma and liver acetaminophen-protein adducts and liver glutathione levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. *Toxicology and Applied Pharmacology* 269: 240-249, 2013.
278. Williams, C.D., McGill, M.R., Yan, H.M., Farhood, A., and **Jaeschke, H.**: Fas receptor-deficient *lpr* mice are protected against acetaminophen hepatotoxicity due to higher glutathione synthesis and enhanced detoxification of oxidant stress. *Food and Chemical Toxicology* 58: 228-235, 2013.
279. **Jaeschke, H.**: Toxic Responses of the Liver. (Invited Review). In: Casarett and Doull's Toxicology, 8th edition; (Klaassen, C.D., ed.), McGraw Hill Publishing, pp. 639-664, 2013.

280. **Jaeschke, H.**, and Woolbright, B.L.: TNF- α induced apoptosis during hepatic ischemia reperfusion injury? (Letter). *Shock* **40**: 75-76, 2013.
281. **Jaeschke, H.**, and McGill, M.R.: Serum glutamate dehydrogenase – biomarker for liver cell death or mitochondrial dysfunction? (Letter). *Toxicological Sciences* **134**: 221–222, 2013.
282. McGill, M.R., and **Jaeschke, H.**: Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis (Invited Review). *Pharmaceutical Research* **30**: 2174-2187, 2013.
283. Godoy, P., Hewitt, N.J., Albrecht, U., Andersen, M.E., Ansari, N., Bhattacharya, S., Bode, J.G., Bolleyn, J., Borner, C., Böttger, J., Braeuning, A., Budinsky, R.A., Burkhardt, B., Cameron, N.R., Camussi, G., Cho, C.S., Choi, Y.J., Rowlands, J.C., Dahmen, U., Damm, G., Dirsch, O., Donato, M.T., Dong, J., Dooley, S., Drasdo, D., Eakins, R., Sa Ferreira, K., Fonsato, V., Fraczek, J., Gebhardt, R., Gibson, A., Glanemann, M., Goldring, C.E.P., Gomez-Lechon, M.J., Groothuis, G.M.M., Gustavsson, L., Guyot, C., Hallifax, D., Hammad, S., Hayward, A., Häussinger, D., Hellerbrand, C., Hewitt, P., Hoehme, S., Holzhütter, H.G., Houston, J.B., Hrach, J., Ito, K., **Jaeschke, H.**, Keitel, V., Kelm, J.M., Park, B.K., Kordes, C., Kullak-Ublick, G.A., LeCluyse, E.L., Lu, P., Luebke-Wheeler, J., Lutz, A., Maltman, D.J., Matz-Soja, M., McMullen, P., Merfort, I., Messner, S., Meyer, C., Mwinyi, J., Naisbitt, D.J., Nussler, A.K., Olinga, P., Pampaloni, F., Pi, J., Pluta, L., Przyborski, S.A., Ramachandran, A., Rogiers, V., Rowe, C., Schelcher, C., Schmich, K., Schwarz, M., Singh, B., Stelzer, E.H.K., Stieger, B., Stöber, R., Sugiyama, Y., Tetta, C., Thasler, W.E., Vanhaecke, T., Vinken, M., Weiss, T.S., Widera, A., Woods, C.G., Xu, J.J., Yarborough, K.M., and Hengstler, J.G.: Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. (Invited Review). *Archives of Toxicology* **87**: 1315-1530, 2013.
284. Ni, H.M., Williams, J.A., **Jaeschke, H.**, and Ding, W.X.: Autophagy/mitophagy and mitochondrial spheroids are induced in specific zones of the liver: an adaptive response to limit acetaminophen-induced necrosis? (Invited Review). *Redox Biology* **1**: 427-432, 2013.
285. McGill, M.R., and **Jaeschke H.**: Apoptosis or necrosis in acetaminophen-induced acute liver failure in humans? New insights from mechanistic biomarkers. (Invited Editorial). *Critical Care Medicine* **41**: 2653-2654, 2013.
286. Vinken, M., Landesmann, B., Goumenou, M., Vinken, S., Shah, I., **Jaeschke, H.**, Willett, C., Whelan, M., and Rogiers, V.: Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. *Toxicological Sciences* **136**: 97-106, 2013.

287. Ramachandran, A., McGill, M.R., Xie, Y., Ni, H.M., Ding, W.X., and **Jaeschke, H.**: The receptor interacting kinase protein 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. *Hepatology* 58: 2099-2108, 2013.
288. Fickert, P., Krones, E., Pollheimer, M.J., Thueringer, A., Moustafa, T., Silbert, D., Halilbasic, E., Yang, M., **Jaeschke, H.**, Stokman, G., Wells, R.G., Eller, K., Rosenkranz, A.R., Eggertsen, G., Langner, C., Denk, H., and Trauner, M.: Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. *Hepatology* 58: 2056-2069, 2013.
289. Du, K., Williams, C.D., McGill, M.R., Xie, Y., Farhood, A., Vinken, M., and **Jaeschke, H.**: The gap junction inhibitor 2-aminoethoxy-diphenyl borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation. *Toxicology and Applied Pharmacology* 273: 484-491, 2013.
290. Woolbright, B.L., Antoine, D.J., Jenkins, R.E., Bajt, M.L., Park, B.K., and **Jaeschke, H.**: Plasma biomarkers of liver injury and inflammation demonstrate lack of apoptosis during obstructive cholestasis in mice. *Toxicology and Applied Pharmacology* 273: 524-531, 2013.
291. Yang, M., Ramachandran, A., Yan, H.M., Woolbright, B.L., Copple, B.L., Fickert, P., Trauner, M., and **Jaeschke, H.**: Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. *Toxicology Letters* 224: 186-195, 2014.
292. Williams, C.D., McGill, M.R., Lebofsky, M., Bajt, M.L., and **Jaeschke, H.**: Protection against acetaminophen-induced liver injury by allopurinol is dependent on aldehyde oxidase-mediated liver preconditioning. *Toxicology and Applied Pharmacology* 274: 417-424, 2014.
293. **Jaeschke, H.**: Interleukin-4 and acetaminophen hepatotoxicity: A story of conflicting results and conclusions (Letter). *Inflammation Research* 63: 171-172, 2014.
294. McGill, M.R., Li, F., Sharpe, M.R., Williams, C.D., Curry, S.C., Ma, X., and **Jaeschke, H.**: Acylcarnitines as biomarkers for mitochondrial dysfunction after acetaminophen overdose in mice and humans. *Archives of Toxicology* 88: 391-401, 2014.
295. Williams, C.D., Bajt, M.L., Sharpe, M.R., McGill, M.R., Farhood, A., and **Jaeschke, H.**: Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans. *Toxicology and Applied Pharmacology* 275: 122-133, 2014.
296. McGill, M.R., Cao, M., Svetlov, A., Sharpe, M.R., Williams, C.D., Curry, S.C., Farhood, A., **Jaeschke, H.**, and Svetlov, S.I.: Argininosuccinate synthetase is an early

- plasma biomarker of liver injury and active cell death during acetaminophen hepatotoxicity in mice and humans. *Biomarkers* 19: 222-230, 2014.
297. Woolbright, B.L., Li, F., Xie, Y., Fickert, P., Trauner, M., and **Jaeschke, H.**: Lithocholic acid feeding triggers direct hepatotoxicity independent of neutrophil function in mice. *Toxicology Letters* 228: 56-66, 2014.
 298. McGill, M.R., Ramachandran, A., and **Jaeschke, H.**: Oxidant stress and drug-induced hepatotoxicity (Invited Review). In: *Systems Biology of Free Radicals and Anti-Oxidants*; (Laher, I., ed.), Springer Verlag, Berlin, pp. 1757-1785, 2014.
 299. McGill, M.R., and **Jaeschke, H.**: Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: From preclinical models to patients. *Expert Opinion on Drug Metabolism and Toxicology* 10: 1005-1017, 2014.
 300. Ward, J., Kanchagar, C., Veksler-Lublinsky, I., Lee, R., McGill, M.R., **Jaeschke, H.**, Curry, S.C., and Ambros, V.: Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity and ischemic hepatitis. *Proceedings of the National Academy of Sciences, USA* 111: 12169-12174, 2014.
 301. Ni, H.M., Woolbright, B.L., Williams, J., Copple, B.L., Cui, W., Luyendyk, J.P., **Jaeschke, H.**, and Ding, W.X.: Nrf2 mediates the development of fibrosis and tumorigenesis in mice with a hepatocyte knock-out of autophagy. *Journal of Hepatology* 61: 617-625, 2014.
 302. Xie, Y., McGill, M.R., Dorko, K., Kumer, S.C., Schmitt, T.M., Forster, J., and **Jaeschke, H.**: Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. *Toxicology and Applied Pharmacology* 279: 266-274, 2014.
 303. **Jaeschke, H.**, Xie, Y., and McGill, M.R.: Acetaminophen-induced liver injury: From animal models to humans. *Journal of Clinical and Translational Hepatology* 2: 153-161, 2014.
 304. McGill, M.R., Staggs, V.S., Sharpe, M.R., Lee, W.M., **Jaeschke, H.**, and Acute Liver Failure Study Group: Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. *Hepatology* 60: 1336-1345, 2014.
 305. Du, K., Williams, C.D., McGill, M.R., and **Jaeschke, H.**: Lower susceptibility of female mice to acetaminophen hepatotoxicity: Role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase. *Toxicology and Applied Pharmacology* 281: 58-66, 2014.
 306. Yang, M., Antoine, D.J., Weemhoff, J.L., Jenkins, R.E., Park, B.K., and **Jaeschke, H.**: Biomarkers distinguish apoptotic and necrotic cell death during hepatic ischemia-reperfusion injury in mice. *Liver Transplantation* 20: 1372-1382, 2014.

307. Willett, C., Rae, J.C., Goyak, K.O., Minsavage, G., Westmoreland, C., Andersen, M., Avigan, M., Duché, D., Hartung, T., **Jaeschke, H.**, Kleensang, A., Landesmann, B., Toole, C., Rowan, A., Schultz, T., Seed, J., Senior, J., Shah, I., Subramanian, K., Vinken, M., and Watkins, P.: Workshop Report: Building shared experience to advance practical application of pathway-based toxicology: Liver toxicity mode-of-action. *ALTEX* 31: 500-519, 2014.
308. Woolbright, B.L., McGill, M.R., Staggs, V.S., Winefield, R.D., Gholami, P., Olyae, M., Sharpe, M.R., Curry, S.C., Lee, W.M., **Jaeschke, H.**, and the Acute Liver Failure Study Group. Glycodeoxycholic acid levels as prognostic serum biomarker in acetaminophen-induced acute liver failure patients. *Toxicological Sciences* 142: 436-444, 2014.
309. **Jaeschke, H.** and Bajt, M.L.: Mechanisms of Acetaminophen Hepatotoxicity (Invited Review). In: *Reference Module in Biomedical Sciences*. Elsevier. pp. 1-20, 2014. doi: 10.1016/B978-0-12-801238-3.02108-5.
310. Woolbright, B.L., Williams, C.D., McGill, M.R., and **Jaeschke, H.**: Liver Toxicity (Invited Review). In: *Reference Module in Biomedical Sciences*. Elsevier. Pp. 1-11, 2014. doi: 10.1016/B978-0-12-801238-3.00205-1.
311. Woolbright, B.L., and **Jaeschke, H.**: Critical Factors in Assessment of Cholestatic Liver Injury *In Vitro* (Invited Review). In *Protocols in In Vitro Hepatocyte Research*. Vinken, M., and Rogiers, V., eds. Springer Verlag, pp. 363-376, 2015.
312. Woolbright, B.L., Dorko, K., Antoine, D.J., Clarke, J., Gholami, P., Li, F., Kumer, S.C., Schmitt, T.M., Forster, J., Fan, F., Jenkins, R.E., Park, B.K., Hagenbuch, B., Olyae, M., and **Jaeschke, H.**: Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. *Toxicology and Applied Pharmacology* 283: 168-177, 2015.
313. **Jaeschke, H.**: Commentary to Choi et al. (2015): CCR5 knockout mice with C57BL6 background are resistant to acetaminophen-mediated hepatotoxicity due to decreased macrophages migration into the liver. *Archives of Toxicology* 89: 807-808, 2015.
314. Ramachandran, A., Lebofsky, M., Yan, H.M., Weinman, S.A., **Jaeschke, H.**: Hepatitis C virus structural proteins can exacerbate or ameliorate acetaminophen-induced liver injury in mice. *Archives of Toxicology* 89: 777-783, 2015.
315. **Jaeschke, H.**, and McGill, M.R.: Cytochrome P450-derived versus mitochondrial oxidant stress in acetaminophen hepatotoxicity (Letter). *Toxicology Letters* 235: 216-217, 2015.

316. Du, K., McGill, M.R., Bajt, M.L., Xie, Y., and **Jaeschke, H.**: Resveratrol prevents protein nitration and release of endonucleases from mitochondria during acetaminophen hepatotoxicity. *Food and Chemical Toxicology* 81: 62-70, 2015.
317. Williams, J.A., Ni, H.M., Haynes, A., Manley, S., Li, Y., **Jaeschke, H.**, and Ding, W.X.: Chronic deletion and acute knockdown of Parkin have differential responses to acetaminophen-induced mitophagy and liver injury in mice. *Journal of Biological Chemistry* 290: 10934-10946, 2015.
318. Tsuchiya, H., da Costa, K.A., Lee, S.M., Renga, B., **Jaeschke, H.**, Yang, Z., Orena S.H., Goedken, M., Zhang, Y., Kong, B., Lebofsky, M., Rudraiah, S., Smalling, R., Guo, G., Fiorucci, S., Zeisel, S.H., and Wang, L.: Nuclear receptor SHP and FoxA1 crosstalk is critical to maintain oscillatory homocysteine homeostasis. *Gastroenterology* 148: 1012-1023, 2015.
319. Xie, Y., Ramachandran, A., Breckenridge, D.G, Liles, J.T., Lebofsky, M., Farhood, A., and **Jaeschke, H.**: Inhibitor of apoptosis signal-regulating kinase 1 protects against acetaminophen hepatotoxicity in mice. *Toxicology and Applied Pharmacology* 286: 1-9, 2015.
320. McGill, M.R., and **Jaeschke, H.**: MicroRNAs as signaling mediators and biomarkers of drug-induced liver injury (Invited Review). *Journal of Clinical Medicine* 4: 1063-1078, 2015.
321. McGill, M.R., Du, K., Xie, Y., Bajt, M.L., Ding, W.X., and **Jaeschke, H.**: The role of c-jun N-terminal kinase and receptor interacting protein 3 kinase in furosemide-induced liver injury. *Xenobiotica* 45: 442-449, 2015.
322. McGill, M.R., Williams, C.D. and **Jaeschke, H.**: Liver Toxicology (Invited Review). In: Mammalian Toxicology; Abou-Donia, M.B., ed.), John Wiley & Son, Ltd., pp. 453-472, 2015.
323. McGill, M.R. and **Jaeschke, H.**: Oxidative stress in acute liver failure. (Invited Review). In *Studies on Hepatic Disorders*, Albano, E., and Parola, M., eds., Springer Verlag, pp. 199-214, 2015.
324. McGill, M.R., and **Jaeschke, H.**: Early biomarkers of hepatocyte necrosis. In: *Translational Bioinformatics (Volume: Single Cell Sequencing and Systems Immunology)*, Wang, X.D., ed., Springer Publisher, pp. 143-154, 2015.
325. Gerbes, A.L., and **Jaeschke, H.**: Preface. Falk Workshop. *The Challenge of Drug-Induced Liver Injury (DILI)*. *Digestive Diseases* 33: 457, 2015.
326. **Jaeschke, H.**: Acetaminophen - dose-dependent drug hepatotoxicity and acute liver failure in patients (Invited Review). *Digestive Diseases* 33: 464-471, 2015.

327. Woolbright, B.L., and **Jaeschke, H.**: Sterile inflammation in acute liver injury: myth or mystery? (Invited Editorial). *Expert Review of Gastroenterology & Hepatology* **8**: 1027-1029, 2015.
328. Woolbright, B.L., and **Jaeschke, H.**: Xenobiotic and endobiotic mediated interactions between the cytochrome P450 system and the inflammatory response in the liver (Invited Review). In: J.P. Hardwick, editor, *Advances in Pharmacology*, Vol. 74, Burlington: Academic Press, pp. 131-161, 2015.
329. Xie, Y., McGill, M.R., Cook, S.F., Sharpe, M.R., Winefield, R. D., Wilkins, D.G., Rollins, D.E., and **Jaeschke, H.**: Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells. *Xenobiotica* **45**: 921-929, 2015.
330. Miyakawa, K., Joshi, N., Sullivan, B.P., Albee, R., Brandenberger, C., **Jaeschke, H.**, McGill, M.R., Scott, M.A., Ganey, P.E., Luyendyk, J.P., and Roth, R.A. Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. *Blood* **126**: 1835-1843, 2015.
331. Xie, Y., Woolbright, B.L., Kos, M., McGill, M.R., Dorko, K., Kumer, S.C., Schmitt, T.M., and **Jaeschke, H.**: Lack of direct cytotoxicity of extracellular ATP against hepatocytes: Potential role in the mechanism of acetaminophen hepatotoxicity. *Journal of Clinical and Translational Research* **2**: 100-106, 2015.
332. Van Golen, R.F., Stevens, K.M., Colarusso P., **Jaeschke, H.** and Heger, M.: Platelet aggregation but not activation and degranulation during the acute post-ischemic reperfusion phase in livers with no underlying disease. *Journal of Clinical and Translational Research* **2**: 107-115, 2015.
333. McGill, M.R. and **Jaeschke, H.**: A direct comparison of methods used to measure oxidized glutathione in biological samples: 2-vinylpyridine and N-ethylmaleimide. *Toxicological Mechanisms and Methods* **25**: 589-595, 2015.
334. McGill, M.R., Xie, Y., and **Jaeschke, H.**: Oxidative stress and signaling in the liver (Invited Review). In: *Signaling Pathways in Liver Disease*, 3rd edition; Dufour, J.F., Clavien, P.A., eds., Wiley-Blackwell, Oxford; pp. 469-478, 2015.
335. **Jaeschke, H.**, and Du, K.: Benzyl alcohol: A novel treatment for acetaminophen overdose? (Letter) *Hepatology* **62**: 1641-1642, 2015.
336. McGill, M.R., and **Jaeschke, H.**: Mitochondrial biomarkers of liver disease. In: *Mitochondria and Liver Disease*; Kaplowitz, N., and Han, D., eds., CRC Press, pp. 265-281, 2015.

337. Du, K., Xie, Y., McGill, M.R. and **Jaeschke, H.**: Pathophysiological significance of c-jun *N*-terminal kinase in acetaminophen hepatotoxicity (Invited Review). *Expert Opinion on Drug Metabolism and Toxicology* 11: 1769-1779, 2015.
338. Du, K., McGill, M.R., Xie, Y., and **Jaeschke, H.**: Benzyl alcohol protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes but causes mitochondrial dysfunction and cell death at higher doses. *Food and Chemical Toxicology* 86: 253-261, 2015.
339. Xie, Y., McGill, M.R., Du, K., Dorko, K., Kumer, S.C., Schmitt, T.M., Ding, W.X., and **Jaeschke, H.**: Mitochondrial protein adducts formation and mitochondrial dysfunction contribute to *N*-acetyl-*m*-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes. *Toxicology and Applied Pharmacology* 289: 213-222, 2015.
340. McGill, M.R., Du, K., Weemhoff, J.L., and **Jaeschke, H.**: Critical review of resveratrol in xenobiotic-induced hepatotoxicity (Invited Review). *Food and Chemical Toxicology* 86: 309-318, 2015.
341. Guicciardi, M.E., Gores, G.J., and **Jaeschke, H.**: Acetaminophen knocks on death's door and RIP1 kinase answers. (Invited Editorial). *Hepatology* 62: 1664-1666, 2015.
342. Vairetti, M., **Jaeschke, H.**, Monbaliu, D., Kim, J.S., and Ferrigno, A. Innovative pharmacological/therapeutical approaches against hepatic ischemia/reperfusion injury (Editorial). *Biomedical Research International* Article ID 918583, 2015. doi:10.1155/2015/918583.
343. Willebrords, J., Crespo Yanguas, S., Maes, M., Decrock, E., Wang N., Leybaert, L., da Silva, T.C., Alves Pereira, I.V., **Jaeschke, H.**, Cogliati, B., Vinken, M.: Structure, regulation and function of gap junctions in liver (Review). *Cell Communication and Adhesion* 22: 29-37, 2015.
344. Maes, M., Vinken, M., and **Jaeschke, H.**: Experimental models of hepatotoxicity related to acute liver failure (Invited Review). *Toxicology and Applied Pharmacology* 290: 86-97, 2016.
345. Ding, W.X., and **Jaeschke, H.**: Autophagy in macrophages regulates the inflammasome and protects against liver injury (Invited Editorial). *Journal of Hepatology* 64: 16-18, 2016.
346. **Jaeschke, H.**: Acetaminophen hepatotoxicity and sterile inflammation: the mechanism of protection of chlorogenic acid (Letter). *Chemico-Biological Interactions* 243: 148-149, 2016.

347. Woolbright, B.L., McGill, M.R., Yan, H.M., and **Jaeschke, H.**: Bile acid-induced toxicity in HepaRG cells recapitulates the response in primary human hepatocytes. *Basic & Clinical Pharmacology and Toxicology* 118: 160-167, 2016.
348. Michaut, A., Le Guillou, D., Moreau, C., Bucher, S., McGill, M.R., Martinais, S., Gicquel, T., Morel, I., Robin, M.A., **Jaeschke, H.**, and Fromenty, B.: A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: application to acetaminophen. *Toxicology and Applied Pharmacology* 292: 40-55, 2016.
349. Hu, J.T., Ramshesh, V.K., McGill, M.R., **Jaeschke, H.**, and Lemasters, J.J.: Low dose acetaminophen induces reversible mitochondrial dysfunction associated with transient c-jun N-terminal kinase activation in mouse liver. *Toxicological Sciences* 150: 204-215, 2016.
350. Woolbright, B.L., and **Jaeschke, H.**: Therapeutic targets for cholestatic liver injury (Invited Review). *Expert Opinion on Therapeutic Targets* 20: 463-475, 2016.
351. Du, K., and **Jaeschke, H.**: Liuweiwuling tablets protect against acetaminophen hepatotoxicity: What is the protective mechanism? (Commentary) *World Journal of Gastroenterology* 22: 3302-3304, 2016.
352. Maes, M., McGill, M.R., da Silva, T.C., Abels, C., Lebofsky, M., Monteiro de Araújo, C.M., Tiburcio, T., Veloso Alves Pereira, I., Willebrords, J., Crespo Yanguas, S., Farhood, A., Beschin, A., Van Ginderachter, J., Zaidan Dagli, M.L., **Jaeschke, H.**, Cogliati, B., and Vinken, M.: Involvement of connexin43 in acetaminophen-induced liver injury. *Biochimica et Biophysica Acta: Molecular Basis of Disease* 1862: 1111-1121, 2016.
353. Maes, M., McGill, M.R., da Silva, T.C., Lebofsky, M., Monteiro de Araújo, C.M., Tiburcio, T., Veloso Alves Pereira, I., Willebrords, J., Crespo Yanguas, S., Farhood, A., Zaidan-Dagli, M.L., **Jaeschke, H.**, Cogliati, B., and Vinken, M.: Connexin32: a mediator of acetaminophen-induced liver injury? *Toxicology Mechanisms and Methods* 26: 88-96, 2016.
354. McGill, M.R., Kennon-McGill, S., Durham, D., and **Jaeschke H.**: Hearing, reactive metabolite formation, and oxidative stress in cochleae after a single acute overdose of acetaminophen: an *in vivo* study. *Toxicology Mechanisms and Methods* 26: 104-111, 2016.
355. Woolbright, B.L., and **Jaeschke, H.**: Neurologic cues modulate immune-mediated liver injury and regeneration. (Invited Editorial). *Hepatology* 63: 1427-1429, 2016.
356. **Jaeschke, H.**: Mechanisms of acetaminophen hepatotoxicity: Do we need JNK for cell death? (Letter) *Gastroenterology* 151: 371-372, 2016.

357. Hu, J.T., Kholmukhamedov, A., Lindsey, C., Beeson, C., **Jaeschke, H.**, and Lemasters J.J.: Translocation of iron from lysosomes to mitochondria during acetaminophen-induced hepatocellular injury: Protection by starch-desferal and minocycline. *Free Radical Biology and Medicine* 97: 418-426, 2016.
358. Ni, H.M., McGill, M.R., Chao, X.J., Du, K., Williams, J.A., Xie, Y., Dorko, K., **Jaeschke, H.**, and Ding, W.X.: Removal of acetaminophen-protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. *Journal of Hepatology* 65: 354-362, 2016. PMID: PMC4955750
359. Ni, H.M., McGill, M.R., Chao, X.J., Woolbright, B.L., **Jaeschke, H.**, and Ding, W.X.: Caspase inhibition prevents TNF- α -induced apoptosis and promotes necrotic cell death in mouse hepatocytes *in vivo* and *in vitro*. *American Journal of Pathology* 186: 2623-2636, 2016. (Press Release) PMID: PMC5222974
360. Du, K., Ramachandran, A., and **Jaeschke, H.**: Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential (Review). *Redox Biology* 10: 148-156, 2016. PMID: PMC5065645
361. Woolbright, B.L., and **Jaeschke, H.**: Noncoding RNAs as therapeutics for acetaminophen-induced liver injury (Invited Editorial). *Stem Cell Investigation* 3: 54, 2016. PMID: PMC5067361
362. Duan, L., Davis, J.S., Woolbright, B.L., Du, K., Cahkraborty, M., Weemhoff, J.L., **Jaeschke, H.**, and Bourdi, M.: Differential susceptibility to acetaminophen-induced liver injury in sub-strains of C57BL/6 mice: 6N versus 6J. *Food and Chemical Toxicology* 98: 107-118, 2016. PMID: PMC5123947
363. Du, K., Ramachandran, A., Weemhoff, J.L., Chavan, H., Xie, Y., Krishnamurthy, P., and **Jaeschke, H.**: Metformin protects against acetaminophen hepatotoxicity by attenuation of mitochondrial oxidant stress and dysfunction. *Toxicological Sciences* 154: 214-226, 2016. PMID: PMC5139063
364. Ramachandran, A., and **Jaeschke, H.**: Experimental models of hepatotoxicity for the testing of natural products. In: *Elsevier Reference Module in Chemistry, Molecular Sciences and Chemical Engineering*; Reedijk, J. (ed.), Waltham, MA: Elsevier. 2016, pp. 1-9. doi:10.1016/B978-0-12-409547-2.11715-9.
365. McGill, M.R., Woolbright, B.L., Weemhoff, J.L., and **Jaeschke, H.**: Mechanistic Biomarkers in Liver Diseases (Invited Review). In: *Biomarkers in Liver Disease*, Patel, V.B., and Preedy, V. (editors), Biomarkers in Disease: Methods, Discoveries and Applications. Springer Science, Dordrecht, 2017; pp. 71-97 (DOI: 10.1007/978-94-007-7675-3_5).

366. Woolbright, B.L., Williams, C.D., Ni, H.M., Kumer, S., Schmitt, T., Kane, B., and **Jaeschke, H.**: Oncotic necrosis predominates microcystin-LR induced liver injury in primary human hepatocytes. *Toxicol* 125: 99-109, 2017. PMID: PMC5193107
367. Du, K., Farhood, A., and **Jaeschke H.**: Mitochondria-targeted antioxidant Mito-Tempo protects against acetaminophen hepatotoxicity. *Archives of Toxicology* 91: 761-773, 2017. PMID: PMC5033665
368. Bhushan, B., Chavan, H., Borude, P., Xie, Y., Du, K., McGill, M.R., Lebofsky, M., **Jaeschke, H.**, Kasturi, P., and Apte, U.: Dual role of epidermal growth factor receptor in liver injury and regeneration after acetaminophen overdose in mice. *Toxicological Sciences* 155: 363-378, 2017.
369. Weemhoff, J.L., Woolbright, B.L., Jenkins, R.E., McGill, M.R., Sharpe, M.R., Olson, J.C., Antoine, D.J., Curry, S.C., and **Jaeschke, H.**: Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis. *Liver International* 37: 377-384, 2017. PMID: PMC5243938
370. Woolbright, B.L., and **Jaeschke, H.**: Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure (Invited Review). *Journal of Hepatology* 66: 836-848, 2017. PMID: PMC5362341
371. Ramachandran, A., and **Jaeschke, H.**: PGAM5: A new player in immune-mediated liver injury (Invited Editorial). *Gut* 66: 567-568, 2017. PMID: PMC5479066
372. Woolbright, B.L., and **Jaeschke, H.**: Mechanisms of acetaminophen-induced liver injury. In: *Cellular Injury in Liver Diseases*, Ding, WX, Yin, XM (eds.), Springer Int. Publ., pp. 55-76, 2017.
373. Ramachandran, A., and Jaeschke, H.: Acetaminophen. In: *Liver Pathophysiology: Therapies and Antioxidants*, Muriel, P. (ed.), Elsevier, pp. 101-112, 2017.
374. Woolbright, B.L., Ding, W.X., and **Jaeschke, H.**: Caspase inhibition for the treatment of liver disease: Friend or Foe? (Invited Editorial) *Expert Review in Gastroenterology and Hepatology* 11: 397-399, 2017. PMID: PMC5493036
375. **Jaeschke, H.**, and Ramachandran, A.: Mechanisms of drug-induced hepatotoxicity: A translational research perspective - Preface. *Journal of Clinical and Translational Research* 3(S1), 2017.
376. Ramachandran, A., and **Jaeschke, H.**: Intracellular signaling mechanisms of acetaminophen-induced cell death and their translation to the human pathophysiology (Invited Review). *Journal of Clinical and Translational Research* 3(S1): 157-169, 2017. PMID: PMC5489132

377. Woolbright, B.L., and **Jaeschke, H.**: The impact of sterile inflammation in acute liver injury (Invited Review). *Journal of Clinical and Translational Research* 3(S1): 170-188, 2017. PMID: PMC5488807
378. Maes, M., McGill, M.R., da Silva, T.C., Abels, C., Lebofsky, M., Weemhoff, J.L., Tiburcio, T., Veloso Alves Pereira, I., Willebrods, J., Crespo Yanguas, S., Farhood, A., Beschin, A., Van Ginderachter, J.A., Penuela, S., **Jaeschke, H.**, Cogliati, B., and Vinken, M. Inhibition of pannexin1 channels alleviates acetaminophen-induced hepatotoxicity. *Archives of Toxicology* 91: 2245-2261, 2017. PMID: PMC5654513
379. McGreal S.R., Karim Rumi, M.A., Soares, M.J., Woolbright, B.L., **Jaeschke, H.**, and Apte, U.: Deletion of estrogen receptor alpha in rats accelerates compensatory liver regeneration after carbon tetrachloride-induced acute liver injury. *International Journal of Toxicology* 36: 199-206, 2017. PMID: PMC5535772
380. Maes, M., Crespo Yanguas, Willebrods, J., Weemhoff, J.L., da Silva, T.C., Decrock, E., Lebofsky, M., Veloso Alves Pereira, I., Leybaert L., Farhood, A., **Jaeschke, H.**, Cogliati, B., and Vinken, M.: Connexin hemichannel blocking reduces drug-induced liver injury in mice. *Toxicology Letters* 278: 30-37, 2017. PMID: 28687253
381. Du, K., Ramachandran, A., McGill, M.R., Mansouri, A., Asselah, T., Farhood, A., Woolbright, B.L., Ding, W.X., and **Jaeschke, H.**: Induction of mitochondrial biogenesis protects against acetaminophen hepatotoxicity. *Food and Chemical Toxicology* 108: 339-350, 2017. PMID: PMC5584682
382. Woolbright, B.L., Bridges, B.W., Dunn, W., Olson, J., Weinman, S.A., and **Jaeschke, H.**: Cell death and prognosis of mortality in alcoholic hepatitis patients using plasma keratin-18. *Gene Expression: The Journal of Basic Liver Research* 17: 301-312, 2017.
383. **Jaeschke, H.** and Ramachandran, A.: Cellular Antioxidant Defense Mechanisms (Ms No 10015). *In*: Comprehensive Toxicology, 3rd Edition, C.A. McQueen, ed., Elsevier, in press, 2017.
384. **Jaeschke, H.**, Bajt, M.L., and Ramachandran, A.: Acetaminophen Hepatotoxicity: Cell death signaling mechanisms in hepatocytes (Ms No 10022). *In*: Comprehensive Toxicology, 3rd Edition, C.A. McQueen, ed., Elsevier, in press, 2017.
385. Ramachandran, A. and **Jaeschke, H.**: Oxidative Stress and Acute Hepatic Injury. *Current Opinion in Toxicology* 7: 17-21, 2018.
386. Li, J., Woolbright, B.L., Zhao, W., Wang Y., Matye, D., Hagenbuch, B., **Jaeschke, H.**, Li, T.: Sortilin 1 loss-of-function protects against cholestatic liver injury by attenuating hepatic bile acid accumulation in bile duct ligated mice. *Toxicological Sciences*, in press, 2018.

387. Woolbright, B.L., and **Jaeschke, H.**: Biomarkers of Mitochondrial Injury after Acetaminophen Overdose: Glutamate Dehydrogenase and Beyond. In: *Mitochondrial Dysfunction and Environmental Toxicants*, Volume 1. Will, Y., and Dykens, J.A., eds., John Wiley & Sons, Inc, pp. 373-382, 2018.
388. **Jaeschke, H.**: Mechanisms of sterile inflammation in acetaminophen hepatotoxicity. (Invited Editorial). *Cellular & Molecular Immunology*, in press.
389. Roth, R.A., **Jaeschke, H.**, and Luyendyk, J.P.: Toxic Responses of the Liver. In: *Casarett and Doull's Toxicology*, 9th edition; (Klaassen, C.D., ed.), McGraw Hill Publishing, in press, 2018.
390. **Jaeschke, H.**, and Naisbitt, D.J.: Immune mechanisms in drug-induced liver injury. In: *Drug-Induced Liver Toxicity* (Chen, M. and Will, Y., eds.), in press, 2018.
391. Ramachandran, A. and **Jaeschke, H.**: Acetaminophen toxicity: Novel insights into mechanisms and future perspectives (Invited Review). *Gene Expression: The Journal of Basic Liver Research*, in press, 2018.
392. Woolbright, B.L. and **Jaeschke, H.**: Alcoholic Hepatitis: Lost in translation (Invited Review). *Journal of Clinical and Translational Hepatology*, in press, 2018.

In addition: **>325 Published Abstracts of Oral and Poster Presentations at National and International Meetings**

Citation Summary of Highly Cited Papers

(Source: Web of Science – All Databases – October 31, 2017)

1. **Jaeschke, H.**, Farhood, A., and Smith, C.W.: Neutrophils contribute to ischemia/reperfusion injury in rat liver *in vivo*. *FASEB Journal* 4: 3355-3359, 1990. **(cited 749 times)**.
2. **Jaeschke, H.**, Gores, G.J., Cederbaum, A.I., Hinson, J.A., Pessayre, D., and Lemasters, J.J.: Mechanisms of hepatotoxicity (Review). *Toxicological Sciences* 65: 166-176, 2002. **(cited 739 times)**.
3. **Jaeschke, H.** and Farhood, A.: Neutrophil and Kupffer cell - induced oxidant stress and ischemia-reperfusion injury in rat liver *in vivo*. *American Journal of Physiology* 260: G355-G362, 1991. **(cited 726 times)**.
4. **Jaeschke, H.**: Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. (Invited Review). *American Journal of Physiology Gastrointest Liver Physiol* 284: G15-G26, 2003. **(cited 541 times)**.
5. **Jaeschke, H.** and Lemasters, J.J.: Apoptosis versus oncotic necrosis in hepatic ischemia-reperfusion injury (Invited Review). *Gastroenterology* 125: 1246-1257, 2003. **(cited 381 times)**.
6. **Jaeschke, H.** and Smith, C.W.: Mechanisms of neutrophil-induced parenchymal cell injury. (Invited Review) *Journal of Leukocyte Biology* 61: 647-653, 1997. **(cited 354 times)**.
7. **Jaeschke, H.**, and Bajt, M.L.: Intracellular signaling mechanisms of acetaminophen-induced liver cell death. (Invited Review) *Toxicological Sciences* 89: 31-41, 2006. **(cited 320 times)**
8. Godoy, P., et al., Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. (Invited Review). *Archives of Toxicology* 87: 1315-1530, 2013. **(cited 311 times)**.
9. **Jaeschke, H.**, Farhood, A., Bautista, A.P., Spolarics, Z., Spitzer, J.J., and Smith, C.W.: Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. *Hepatology* 17: 915-923, 1993. **(cited 292 times)**.
10. **Jaeschke, H.**: Mechanisms of neutrophil-mediated liver cell injury during ischemia-reperfusion and other acute inflammatory conditions. (Invited Review). *American Journal of Physiology Gastrointestinal and Liver Physiology* 290: G1083-G1088, 2006. **(cited 290 times)**.

11. **Jaeschke, H.:** Reactive oxygen and ischemia/reperfusion injury of the liver (Review). *Chemico Biological Interactions* 79: 115-136, 1991. (**cited 284 times**).
12. **Jaeschke, H.,** Fisher, M.A., Lawson, J.A., Simmons, C.A., Farhood, A., and Jones, D.A.: Activation of caspase-3 (CPP32)-like proteases is essential for TNF- α -induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. *Journal of Immunology* 160: 3480-3486, 1998. (**cited 272 times**).
13. **Jaeschke, H.,** Farhood, A., and Smith, C.W.: Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18 - dependent mechanism. *American Journal of Physiology* 261: G1051-G1056, 1991. (**cited 271 times**).
14. Gujral, J.S., Bucci, T.J., Farhood, A., and **Jaeschke, H.:** Mechanism of cell death during hepatic ischemia-reperfusion in rats: Apoptosis or necrosis? *Hepatology* 33: 397-405, 2001. (**cited 269 times**).
15. **Jaeschke, H.,** Farhood, A., Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. *American Journal of Physiology* 264: G801-G809, 1993. (**cited 255 times**).
16. Kon, K., Kim, J.S., **Jaeschke, H.,** and Lemasters, J.J.: Mitochondrial permeability transition in acetaminophen-induced necrotic and apoptotic cell death to cultured mouse hepatocytes. *Hepatology* 40: 1170-1179, 2004. (**cited 255 times**).
17. **Jaeschke, H.,** Knight, T.R., and Bajt, M.L.: The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity (Invited Review). *Toxicology Letters* 144: 279-288, 2003. (**cited 255 times**)
18. **Jaeschke, H.,** McGill, M.R., and Ramachandran, A.: Oxidant stress, mitochondria and intracellular cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity (Invited Review). *Drug Metabolism Reviews* 44: 88-106, 2012. (**cited 251 times**).
19. Farhood, A., McGuire, G.M., Manning, A.M., Miyasaka, M., Smith, C.W., and **Jaeschke, H.:** Intercellular adhesion molecule-1 (ICAM-1) gene expression and its role in neutrophil-induced ischemia-reperfusion injury in the liver. *Journal of Leukocyte Biology* 57: 368-374, 1995. (**cited 233 times**).
20. **Jaeschke, H.,** Smith, C.V., and Mitchell, J.R.: Reactive oxygen species and ischemia-reflow injury in isolated perfused rat liver. *Journal of Clinical Investigations* 81: 1240-1246, 1988. (**cited 230 times**).
21. **Jaeschke, H.,** Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. *Free Radical Research Communications* 15: 277-284, 1991. (**cited 229 times**).

22. Gujral, J.S., Knight, T.R., Farhood, A., Bajt, M.L., and **Jaeschke, H.**: Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? *Toxicological Sciences* 67: 322-328, 2002. **(cited 227 times)**
23. **Jaeschke, H.**: Glutathione disulfide formation and oxidant stress during acetaminophen induced hepatotoxicity in mice in vivo: The protective effect of allopurinol. *Journal of Pharmacology and Experimental Therapeutics* 255: 935-941, 1990. **(cited 219 times)**.
24. **Jaeschke, H.**: Reactive oxygen and mechanisms of inflammatory liver injury (Invited Review). *Journal of Gastroenterology and Hepatology* 15: 718-724, 2000. **(cited 217 times)**.
25. McGill, M.R., Sharpe, M.R., Williams, C.D., Taha, M., Curry, S.C., and **Jaeschke, H.**: Mechanisms of acetaminophen hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. *Journal of Clinical Investigation* 122: 1574-1583, 2012. **(cited 214 times)**.
26. **Jaeschke, H.**: Reactive oxygen and mechanisms of inflammatory liver injury: present concepts (Invited Review). *Journal of Gastroenterology and Hepatology* 26 (Suppl. 1): 173-179, 2011. **(cited 213 times)**.
27. **Jaeschke, H.**, Bautista, A.P., Spolarics, Z., and Spitzer, J.J.: Superoxide generation by neutrophils and Kupffer cells during *in vivo* reperfusion after hepatic ischemia in rats. *Journal of Leukocyte Biology* 52: 377-382, 1992. **(cited 200 times)**.
28. Essani, N.A., Fisher, M.A., Farhood, A., Manning, A.M., Smith, C.W., and **Jaeschke, H.**: Cytokine-induced hepatic intercellular adhesion molecule-1 (ICAM-1) mRNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. *Hepatology* 21: 1632-1639, 1995. **(cited 191 times)**.
29. **Jaeschke, H.**: Mechanisms of oxidant stress-induced acute tissue injury (Invited Review). *Proceedings of the Society of Experimental Biology and Medicine* 209: 104-111, 1995. **(cited 182 times)**.
30. **Jaeschke, H.** and Mitchell, J.R.: Mitochondria and xanthine oxidase both generate reactive oxygen species after hypoxic damage in isolated perfused rat liver. *Biochemical Biophysical Research Communications* 160: 140-147, 1989. **(cited 178 times)**.
31. Knight, T.R., Kurtz, A., Bajt, M.L., Hinson, J.A., and **Jaeschke, H.**: Vascular and hepatocellular peroxynitrite formation during acetaminophen-induced liver injury: Role of mitochondrial oxidant stress. *Toxicological Sciences* 62: 212-220, 2001. **(cited 177 times)**.

32. Gujral, J.S., Farhood, A., Bajt, M.L., and **Jaeschke, H.**: Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. *Hepatology* 38: 355-363, 2003. (cited **174 times**).
33. Fickert, P., Wagner, M., Marschall, H.U., Fuchsbichler, A., Zollner, G., Tsybrovskyy O., Zatloukal, K., Liu, J., Waalkes, M.P., Cover, C., Denk, D., Hofmann, A.F., **Jaeschke, H.**, and Trauner, M.: 24-*nor*Ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in *Mdr2 (Abcb4)* knockout mice. *Gastroenterology* 130: 465-481, 2006. (cited **175 times**)
34. Bajt, M.L., Knight, T.R., Lemasters, J.J., and **Jaeschke, H.**: Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes: protection by *N*-acetyl cysteine. *Toxicological Sciences* 80: 343 - 349, 2004. (cited **172 times**).
35. **Jaeschke, H.**, Smith, C.W., Clemens, M.G., Ganey, P.E., and Roth, R.A.: Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxicity of neutrophils (Review). *Toxicology and Applied Pharmacology* 139: 213-226, 1996. (cited **165 times**).
36. **Jaeschke, H.**: Mechanism of reperfusion injury after warm ischemia of the liver. (Invited Review) *Journal of Hepatobiliary Pancreatic Surgery* 21: 402-408, 1998. (cited **164 times**)
37. Liu, P., McGuire, G.M., Fisher, M.A., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. *Shock* 3: 56-62, 1995. (cited **160 times**).
38. Ramaiah, S.K., and **Jaeschke, H.**: Role of neutrophils in the pathogenesis of acute inflammatory liver injury (Invited Review). *Toxicologic Pathology* 35: 757-766, 2007. (cited **159 times**).
39. Lawson, J.A., Fisher, M.A., Simmons, C.A., Farhood, A., and **Jaeschke, H.**: Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models endotoxin- and Fas-antibody-mediated liver injury. *Hepatology* 28: 761-767, 1998. (cited **155 times**).
40. Antoine, D.J., Jenkins, R.E., Dear, J.W., Williams, D.P., McGill, M.R., Sharpe, M.R., Craig, D.G., Simpson, K.J., **Jaeschke, H.**, and Park, B.K.: Molecular forms of HMGB1 and Keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. *Journal of Hepatology* 56: 1070-1079, 2012. (cited **154 times**).
41. Cover, C., Mansouri, A., Knight, T.R., Bajt, M.L., Lemasters, J.J., Pessayre, D., and **Jaeschke, H.**: Peroxynitrite-induced mitochondrial and endonuclease-mediated

- nuclear DNA damage in acetaminophen hepatotoxicity. *Journal of Pharmacology and Experimental Therapeutics* 315: 879-887, 2005. (cited **151 times**).
42. **Jaeschke, H.**, Williams, C.D., Ramachandran, A., and Bajt, M.L.: Acetaminophen hepatotoxicity and repair: role of sterile inflammation and innate immunity (Invited Review). *Liver International* 32: 8-20, 2012. (cited **149 times**).
 43. **Jaeschke, H.**, and Hasegawa, T.: Role of neutrophils in acute inflammatory liver injury. (Invited Review). *Liver International* 26: 912-919, 2006. (cited **145 times**).
 44. Witthaut, R., Farhood, A., Smith, C.W., and **Jaeschke, H.**: Complement and tumor necrosis factor- α contribute to Mac-1 (CD11b/CD18) upregulation and systemic neutrophil activation during endotoxemia *in vivo*. *Journal of Leukocyte Biology* 55: 105-111, 1994. (cited **145 times**).
 45. Ni, H.M., Bockus, A., **Jaeschke, H.**, and Ding, W.X.: Activation of autophagy protects against acetaminophen hepatotoxicity in mice. *Hepatology* 55: 222-231, 2012. (cited **144 times**).
 46. Lawson, J.A., Farhood, A., Hopper, R.D., Bajt, M.L., and **Jaeschke, H.**: The hepatic inflammatory response after acetaminophen overdose: The role of neutrophils. *Toxicological Sciences* 54: 509-516, 2000. (cited **144 times**).
 47. Chosay, J.G., Essani, N.A., Dunn, C.J., and **Jaeschke, H.**: Neutrophil margination and extravasation in sinusoids and venules of the liver during endotoxin-induced injury. *American Journal of Physiology* 272: G1195-G1200, 1997. (cited **143 times**).
 48. Mathews, W.R., Guido, D.M., Fisher, M.A., and **Jaeschke, H.**: Lipid peroxidation as molecular mechanism of liver cell injury during reperfusion after ischemia. *Free Radical Biology and Medicine* 16: 763-770, 1994. (cited **141 times**).
 49. Adams, D.H., Ju, C., Ramaiah, S., Uetrecht, J.P. and **Jaeschke, H.**: Mechanisms of immune-mediated liver injury (Review). *Toxicological Sciences* 115: 307-321, 2010. (cited **141 times**).
 50. Knight, T.R., Ho, Y.-S., Farhood, A., and **Jaeschke, H.**: Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione. *Journal of Pharmacology and Experimental Therapeutics* 303: 468-475, 2002. (cited **141 times**).
 51. **Jaeschke, H.**, Ho Y.-S., Fisher, M.A., Lawson, J.A., and Farhood, A.: Glutathione peroxidase deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: Importance of an intracellular oxidant stress. *Hepatology* 29: 443-450, 1999. (cited **140 times**).

52. Saito, C., Zwingmann, C., **Jaeschke, H.**: Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and *N*-acetylcysteine. *Hepatology* 51: 246-254, 2010. (**cited 139 times**).
53. Allen, K., **Jaeschke, H.**, and Copple, B.L.: Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. *American Journal of Pathology* 178: 175-186, 2011. (**cited 136 times**).
54. Essani, N.A., McGuire, G.M., Manning, A.M., and **Jaeschke, H.**: Endotoxin-induced activation of the nuclear transcription factor κ B in hepatocytes, Kupffer cells and endothelial cells *in vivo*. *Journal of Immunology* 156: 2956-2963, 1996. (**cited 136 times**).
55. **Jaeschke, H.**: Cellular adhesion molecules: Regulation and role in the pathogenesis of liver disease. (Invited Review) *American Journal of Physiology Gastrointest Liver Physiol* 273: G602-G611, 1997. (**cited 129 times**).
56. **Jaeschke, H.**: Preservation injury: Mechanisms, prevention and consequences (Invited Review). *Journal of Hepatology* 25: 774-780, 1996. (**cited 123 times**).
57. Lawson, J.A., Fisher, M.A., Simmons, C.A., Farhood, A., and **Jaeschke, H.**: Inhibition of Fas receptor (CD95) - induced hepatic caspase activation and apoptosis by acetaminophen in mice. *Toxicology and Applied Pharmacology* 156: 179-186, 1999. (**cited 120 times**).
58. Essani, N.A., Bajt, M.L., Vonderfecht, S.L., Farhood, A., and **Jaeschke, H.**: Transcriptional activation of vascular cell adhesion molecule-1 (VCAM-1) gene *in vivo* and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. *Journal of Immunology*, 158: 5941-5948, 1997. (**cited 118 times**).
59. **Jaeschke, H.**, and Woolbright, B.L.: Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. (Invited Review) *Transplantation Reviews* 26: 103-114, 2012. (**cited 118 times**).
60. **Jaeschke, H.**, Farhood, A., Fisher, M.A., and Smith, C.W.: Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of β_2 integrins and intercellular adhesion molecule-1. *Shock* 6: 351-356, 1996. (**cited 117 times**).
61. McGill, M.R., Yan, H.M., Ramachandran, A., Murray, G.J., Rollins, D., and **Jaeschke, H.**: HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. *Hepatology* 53: 974-982, 2011. (**cited 114 times**).
62. **Jaeschke, H.**, Kleinwaechter, C., and Wendel, A.: The role of acrolein in allyl alcohol-induced lipid peroxidation and liver cell damage in mice. *Biochemical Pharmacology* 36: 51-57, 1987. (**cited 112 times**).

63. Fickert, P., Fuchsbichler, A., Marschall, H.U., Wagner, M., Zollner, G., Krause, R., Zatloukal, K., **Jaeschke, H.**, Denk, H., and Trauner, M.: Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. *American Journal of Pathology* 168: 410-422, 2006. (**cited 112 times**).
64. **Jaeschke, H.**, McGill, M.R., Williams, C.D., and Ramachandran, A.: Acetaminophen hepatotoxicity – a clinically relevant model to test the efficacy of natural products (Invited Review). *Life Sciences* 88: 737-745, 2011. (**cited 112 times**).
65. Saito, C., Lemasters, J.J., and **Jaeschke, H.**: c-Jun-N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity. *Toxicology and Applied Pharmacology* 246: 8-17, 2010. (**cited 112 times**).
66. McGill, M.R., and **Jaeschke, H.**: Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis (Invited Review). *Pharmaceutical Research* 30: 2174-2187, 2013. (**cited 112 times**).
67. Essani, N.A., Fisher, M.A., and **Jaeschke, H.**: Inhibition of NF- κ B activation by dimethyl sulfoxide correlates with suppression of TNF- α formation, reduced ICAM-1 gene transcription and protection against endotoxin-induced liver injury. *Shock* 7: 90-96, 1997. (**cited 109 times**).
68. McGill, M.R., Williams, C.D., Xie, Y., Ramachandran, A., and **Jaeschke, H.**: Acetaminophen-induced liver injury in rats and mice: Comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. *Toxicology and Applied Pharmacology* 264: 387-394, 2012. (**cited 105 times**).
69. **Jaeschke, H.**, Gujral, J.S., and Bajt, M.L.: Apoptotic and oncotic necrosis in liver disease (Invited Review). *Liver International* 24: 85-89, 2004. (**cited 100 times**).

Dr. Jaeschke's "h-index" is 82

(82 manuscripts, each of which have 82 citations or more) as calculated by ISI Web of Knowledge (all databases).

Reference: JE Hirsch. An index to quantify an individual's scientific research output. *PNAS* 2005; 102:16569-16572.

Google Scholar: h-index 93; i10-index 256; >29,000 total citations (10/31/2017)
<https://scholar.google.com/citations?user=TxY3x1QAAAAJ&hl=en>

Invited Research Seminars in Industry and Academia

1. 1982 - Institute of Toxicology, University of Tübingen, Germany.
2. 1984 - Institute of Toxicology, University of Tübingen, Germany.
3. 1985 - Institute of Biochemistry, University of Tübingen, Germany.
4. 1986 - Institute of Lipid Research, Baylor College of Medicine, Houston, Texas.
5. 1987 - Center for Experimental Therapeutics, Baylor College of Medicine, Houston, TX.
6. 1987 - Institute of Toxicology, University of Würzburg, Germany.
7. 1987 - Department of Pharmacology, Baylor College of Medicine, Houston, Texas.
8. 1987 - Department of Biochemistry, University of Tübingen, Germany.
9. 1988 - Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, Texas.
10. 1989 - Boehringer Mannheim GmbH, Penzberg, Germany.
11. 1989 - Institute of Toxicology, University of Würzburg, Germany.
12. 1990 - Department of Pediatrics, Leukocyte Biology Section, Baylor College of Medicine, Houston, Texas.
13. 1990 - Institute of Toxicology, University of Tübingen, Germany.
14. 1990 - Department of Clinical Pharmacology, University of Berne, Switzerland.
15. 1990 - College of Pharmacy, University of Texas, Houston, Texas.
16. 1990 - Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky.
17. 1990 - Drug Discovery, The Upjohn Company, Kalamazoo, Michigan.
18. 1990 - Department of Physiology, LSU Medical Center, New Orleans, Louisiana.
19. 1991 - Drug Safety Unit, Knoll AG, Ludwigshafen, Germany.
20. 1992 - Department of Physiology, LSU Medical Center, New Orleans, Louisiana.
21. 1992 - Upjohn Laboratories, The Upjohn Company, Kalamazoo, Michigan.
22. 1992 - Drug Metabolism Research, The Upjohn Company, Kalamazoo, Michigan.
23. 1992 - Department of Medicine Research Seminar Series, Baylor College of Medicine, Houston, Texas.
24. 1992 - Department of Medical Pharmacology and Toxicology, College of Medicine, Texas A&M University Health Science Center, College Station, Texas.
25. 1993 - Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan.
26. 1993 - Department of Physiology, LSU Medical Center, New Orleans, Louisiana.
27. 1993 - Department of Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan.
28. 1993 - Abteilung Gastroenterologie, Universitätsklinik für Innere Medizin, Jena, Germany.
29. 1993 - Abteilung Allgemeine Chirurgie, Chirurgische Universitätsklinik, Tübingen, Germany.
30. 1993 - Department of Biological Sciences, Western Michigan University, Kalamazoo, Michigan.
31. 1993 - Drug Metabolism Research, Upjohn Laboratories, Kalamazoo, Michigan.
32. 1994 - Department of Anatomy, Cell Biology & Injury Sciences, University of Medicine & Dentistry of New Jersey, Newark, New Jersey.
33. 1994 - Department of Surgery, Mount Sinai School of Medicine, New York, N.Y.

34. 1995 - Department of Physiology and Biophysics, LSU School of Medicine, Shreveport, Louisiana.
35. 1995 - Department of Investigative Toxicology, Eli Lilly and Co., Greenfield, Indiana.
36. 1996 - Department of Pharmacology and Toxicology, School of Pharmacy, University of Connecticut, Storrs, CT.
37. 1996 - Center for Toxicology, Southwest Environmental Health Science Center, The University of Arizona School of Pharmacy, Tucson, AZ.
38. 1996 - Department of Critical Care, Mount Sinai School of Medicine, New York, N.Y.
39. 1997 - USC Liver Disease Research Center, University of Southern California School of Medicine, Los Angeles, CA.
40. 1997 - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
41. 1998 - Department of Surgery, Michigan State University, East Lansing, Michigan.
42. 1998 - Department of Pharmacology and Toxicology, Rutgers University, Piscataway, New Jersey.
43. 1998 - Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan.
44. 1998 - Department of Biology, University of North Carolina, Charlotte, NC.
45. 1998 - Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada.
46. 1998 - Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
47. 1998 - Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
48. 1999 - Department of Biochemistry & Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
49. 1999 - Department of Medicine, University of Tennessee Medical Center, Memphis, Tennessee.
50. 1999 - Arkansas Children's Hospital Research Institute and Nutrient Center, Little Rock, Arkansas.
51. 1999 - Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
52. 2000 - USC Alcohol Research Center, University of Southern California School of Medicine, Los Angeles, CA.
53. 2001 - Department of Biology, University of Arkansas, Fayetteville, Arkansas.
54. 2001 - Department of Physiology and Biophysics, LSU School of Medicine, Shreveport, Louisiana.
55. 2001 - Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
56. 2001 - Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
57. 2002 - Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA.
58. 2002 - Arizona Liver Research Institute, College of Medicine, University of Arizona, Tucson, AZ.
59. 2003 - USC Liver Disease Research Center, University of Southern California School of Medicine, Los Angeles, CA.

60. 2004 - Instituto de Investigaciones Biomédicas de Barcelona (CSIC) / Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
61. 2004 - National Institute of Alcoholism and Alcohol Abuse, Bethesda, MD.
62. 2004 - Center for Developmental Pharmacology and Toxicology, Columbus Children's Research Institute, Columbus, Ohio.
63. 2005 - Department of Pathology, University of Pittsburgh, Pennsylvania.
64. 2005 - Department of Pharmacology and Toxicology, University of Texas A&M, College Station, Texas.
65. 2005 - Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas.
66. 2006 - McNeil Consumer Products Division; Ft. Washington, Pennsylvania.
67. 2006 - Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina.
68. 2007 - Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California.
69. 2007 - Veterans Affairs Medical Center, Kansas City, Missouri.
70. 2007 - Medizinische Klinik und Poliklinik II, Klinikum München-Großhadern Ludwig-Maximilians-Universität München, Munich, Germany.
71. 2007 - Liver Club, University of Kansas Medical Center, Kansas City, Kansas.
72. 2007 - Millenium Pharmaceuticals, Cambridge, Massachusetts. R&D Seminar Series Millennium Science Weekly.
73. 2008 - Liver Club, University of Kansas Medical Center, Kansas City, Kansas.
74. 2008 - Department of Cell Biology and Histology, University of Tromso, Norway.
75. 2009 - Faculty Research Day, University of Kansas Medical Center, Kansas City, Kansas.
76. 2010 - Liver Club, University of Kansas Medical Center, Kansas City, Kansas.
77. 2010 - Center for Transplant Immunology and Immune Therapeutics; Emory University, Atlanta, Georgia.
78. 2011 - Liver Club, University of Kansas Medical Center, Kansas City, Kansas.
79. 2011 - Department of Pathology, University of Pittsburgh, PA.
80. 2011 - Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut.
81. 2011 - Faculty Research Day, University of Kansas Medical Center, Kansas City, Kansas.
82. 2011 - Chair Search Seminar; School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
83. 2012 - Digestive Disease Center at Cincinnati Children's Hospital, Cincinnati, Ohio.
84. 2012 - Center for Free Radical Biology, University of Alabama at Birmingham, Alabama.
85. 2012 - Research Institute for Inflammation and Immunity, University of Calgary, Calgary, Canada.
86. 2012 - Department of Pathology, University of Indiana, Indianapolis, IN.
87. 2012 - Department of Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, MO.
88. 2012 - Department of Pharmacology, Toxicology and Therapeutics, KUMC.
89. 2012 - Center for Molecular Toxicology, Vanderbilt University, Memphis, Tennessee.

90. 2013 – Department of Surgery and Department of Pharmacology, University of Florida, Gainesville, FL.
91. 2014 – Department of Surgery and KUMC Liver Center, University of Kansas Medical Center, Kansas City, KS.
92. 2015 – Liver Research Center, Albert Einstein College of Medicine, Bronx, New York.
93. 2016 – Department of Pathology, Tulane University, College of Medicine, New Orleans, Louisiana.
94. 2016 – Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine; Shanghai, China.
95. 2017 – KUMC Liver Center and Kansas Alcohol Center, University of Kansas Medical Center, Kansas City, KS.

Invited Lectures at National and International Meetings

1. 1990 - 29th Annual Meeting of the Society of Toxicology, Miami, Florida; Symposium: *Mechanisms of Hypoxic Cell Injury*.
2. 1992 - Baseler Liver Week, Basel, Switzerland. International Workshop: *Functions of Glutathione in Gut and Liver*.
3. 1993 - Workshop on Venocclusive Disease in Bone Marrow Transplant Patients, NHLBI, Bethesda, Maryland.
4. 1993 - Workshop on Experimentelle und Klinische Lebertransplantation und Hepatologie, Wilsede, Germany.
5. 1993 - Workshop on the Cell Biology of Trauma, Chapel Hill, North Carolina.
6. 1994 - FASEB Summer Conference: Pathophysiology of the Splanchnic Circulation, Copper Mountain, Colorado.
7. 1995 - 34th Annual Meeting of the Society of Toxicology, Baltimore, Maryland; Symposium: *Mechanisms of Inflammatory Liver Injury: Adhesion Molecules and Cytotoxicity of Neutrophils*.
8. 1995 - Single Topic Symposium of the American Association for the Study of Liver Diseases: *Oxidant Stress and Liver Disease*, Airlie, Virginia.
9. 1995 - Symposium at the Fall Meeting of the Mid-West Society of Toxicology: *Cholestatic Liver Injury and Hepatotoxic Mechanisms*, Chicago, Illinois.
10. 1996 - 8th Int. Symposium on Cells of the Hepatic Sinusoid, Bordeaux, France.
11. 1997 - 4th Int. Congress on the Immune Consequences of Trauma, Shock and Sepsis, Munich, Germany.
12. 1997 - Symposium at the Spring Meeting of the Michigan Regional Chapter of the Society of Toxicology: *Oxidative Stress as a Mechanism of Toxicant Action*, East Lansing, MI.
13. 1997 - AASLD Postgraduate Course; "Liver Injury Update: Clinical Implications and Mechanistic Role of Cells of the Liver", Chicago, IL.
14. 1997 - 48th Annual Meeting of the American Association for the Study of Liver Diseases. Symposium: *Apoptosis*.
15. 1998 - Symposium on *Hepatic and Intestinal Defense Mechanisms*, Göttingen, Germany.

16. 1998 - 20th Annual Conference on Shock, San Antonio, Texas. Symposium: *Chemokines and Parenchymal Cell Adhesion Molecules*.
17. 1998 - 9th Int. Symposium on Cells of the Hepatic Sinusoid, Christchurch, New Zealand.
18. 1999 - American Society of Investigative Pathology, Liver Pathobiology Symposium: *The Inflamed Liver*. Washington, D.C.
19. 1999 - Int. Symposium *Chirurgie der Lebertumoren – Tumorbiologie, Diagnostic, Therapie*. Munich, Germany.
20. 1999 - AASLD Research Workshop: *Ischemia-Reperfusion Injury and Preconditioning*. Dallas, TX.
21. 2000 - 5th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany. Symposium: *Liver Injury - Pathomechanisms and Therapeutic Approaches*.
22. 2000 - Falk Symposium *Hepatology 2000*. Munich, Germany.
23. 2000 - Annual Meeting of the British Association for the Study of the Liver. Southampton, UK. Symposium: *Role of Sinusoidal Liver Cells in Liver Transplantation*.
24. 2000 - 10th Biennial Meeting of the International Society for Free Radical Research, Kyoto, Japan; Session: *Digestive Diseases*.
25. 2001 - 40th Annual Meeting of the Society of Toxicology, San Francisco, CA; Symposium: *Mechanisms of Hepatotoxicity*.
26. 2001 - Annual Meeting of the Research Society on Alcoholism, Montreal, Canada; Satellite Symposium: *Alcoholic Hepatitis: Cellular and Molecular Mechanisms*.
27. 2001 - 6th Congress of the International Society for Organ Sharing, Nagoya, Japan. Plenary Session: *Preservation/Reperfusion Injury*.
28. 2001 - 7th World Congress for Microcirculation, Sydney, Australia; Symposium *Hepatic Microcirculation in Health and Disease*.
29. 2001 - 2nd Int. Conference on Hepatic and Splanchnic Circulation in Health and Disease; Dunedin, New Zealand.
30. 2002 - Experimental Biology '02, New Orleans, LA. Symposium: *Molecular and Cellular Mechanisms of Ischemic Liver Injury*.
31. 2002 - Symposium "*Oxidative Damage*"; Center in Molecular Toxicology at Vanderbilt, Nashville, TN.
32. 2002 - 11th Int. Symposium on Cells of the Hepatic Sinusoid, Tucson, Arizona.
33. 2003 - Meeting of the International Society for the Study of Xenobiotics, Providence, Rhode Island. Basic Course "*Xenobiotic-induced Hepatotoxicity*".
34. 2003 - European Association for Study of Liver Diseases, Postgraduate Course "*NASH, ASH and Hepatotoxicity*". Madrid, Spain.
35. 2003 - European Gastroenterology Week, Madrid, Spain. Symposium "*Novel Strategies for Hepatoprotection*".
36. 2004 - 6th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany.
37. 2004 - Experimental Biology '04, Washington, D.C.; APS Symposium: "*Mediators of Inflammatory Liver Injury*".
38. 2004 - Experimental Biology '04, Washington, D.C.; ASPET Symposium: *Hepatotoxicity: Signaling mechanisms in cell death and survival*.

39. 2004 - Digestive Disease Week 2004; AGA Symposium “*Apoptosis and the Liver*”. New Orleans, Louisiana.
40. 2004 - 3rd International Conference on Idiosyncratic Drug Toxicity, San Diego, CA.
41. 2004 - Single Topic Conference of the Canadian Association for the Study of the Liver. Niagara-on-the-Lake, Canada.
42. 2004 - 12th Int. Symposium on Cells of the Hepatic Sinusoid, Bilbao, Spain.
43. 2004 - Program Project Grant Symposium “*Mechanisms and Consequences of Hepatocellular Injury*”, Shreveport, LA.
44. 2006 - 45nd Annual Meeting of the Society of Toxicology, San Diego, California; Symposium: *Idiosyncratic hepatotoxicity: An antiquated paradigm? – Nonclinical predictive toxicology for liver injury potential*.
45. 2006 - Single Topic Conference: *Alcoholic and Non-Alcoholic Steatohepatitis*, American Association for the Study of Liver Diseases, Atlanta, Georgia.
46. 2006 - Eurotox Congress, Dubrovnik, Croatia; Symposium: *Reactive Oxygen Species in Toxicology*.
47. 2007 - Single Topic Conference: *Vascular Biology and Pathobiology of the Liver*, American Association for the Study of Liver Diseases, Atlanta, Georgia.
48. 2007 - Symposium: *Cell Adhesion in the Immune System*. Bonner Forum Biomedizin, Bonn, Germany.
49. 2007 - International Falk Symposium 162, *Liver Cirrhosis: From Pathophysiology to Disease Management*. Dresden, Germany.
50. 2008 - 1st Liver Center Symposium, University of Kansas Medical Center; Kansas City, Kansas.
51. 2008 - Acetaminophen Symposium. McNeil Pharmaceuticals; Denver, Colorado.
52. 2009 - 48th Annual Meeting of the Society of Toxicology; Baltimore, Maryland. Symposium: *The role of inflammation during metabolic liver disease and drug-induced liver toxicity: novel insights*.
53. 2009 - 10th Annual Western Medical Toxicology Fellowship Conference, San Diego, California.
54. 2009 - Charleston Conference on Mitochondrial Physiology and Pathobiology, Charleston, South Carolina.
55. 2009 – 1st American Society of Transplantation Annual Scientific Exchange, Orlando, Florida.
56. 2010 - Monothematic Conference: *Signaling in the Liver*; European Association for the Study of the Liver (EASL). Amsterdam, Netherlands.
57. 2010 – 3rd Liver Center Symposium, University of Kansas Medical Center; Kansas City, Kansas.
58. 2010 - European Partnership on Alternatives to Animal Testing (EPAA) Workshop on Computational Chemistry and Systems Biology: *Harnessing the Chemistry of Life: Revolutionising Toxicology*. Brussels, Belgium.
59. 2010 - FASEB Summer Research Conference on “Liver Growth, Injury and Metabolism: Basic and Applied Biology”. Snowmass, Colorado.
60. 2010 - FDA DILI-Simulation Expert Focus Group Meeting, Silver Spring, Maryland.
61. 2011 – Symposium: “*HepaRG, Novel Human Hepatic Cells for In Vitro Toxicology*.” 50th Annual Meeting of the Society of Toxicology, Washington, D.C.
62. 2011 - International HepaRG Workshop, Rennes, France.

63. 2011 - Pathogenesis of Liver Injury Forum, Acute Liver Failure Research Group, Dallas, Texas.
64. 2011 - Hepatotoxicity Symposium, Division of Animal Clinical Chemistry Meeting, Raritan, New Jersey.
65. 2011 - Protein Binding Forum, McNeil Consumer Health Care; Denver, Colorado.
66. 2012 - Liver Injury Workshop, Novartis, East Hanover, New Jersey.
67. 2012 - AASLD Clinical Research Single Topic Conference - *Acetaminophen Poisoning*, Atlanta, Georgia.
68. 2013 - Symposium: "Building Shared Experience to Advance Practical Application of Pathway-Based Toxicity: Liver Toxicity Mode of Action". Human Toxicology Project Symposium, Baltimore, Maryland.
69. 2013 - Symposium: "*Understanding Toxicities of Abnormal Lipid Metabolism: Alcoholic, Non-Alcoholic, and Toxicant-Induced Fatty Liver Disease.*" 52th Annual Meeting of the Society of Toxicology, San Antonio, Texas.
70. 2013 - Experimental Biology, ASPET Symposium "*Acetaminophen-induced Hepatotoxicity - Lessons Learned During the Last Four Decades Investigating Mechanisms of Toxicity*". Boston, MA.
71. 2013 - Symposium: "*Molecular Mechanisms of DILI*", The International Liver Congress, Amsterdam, The Netherlands.
72. 2013 - Symposium: "*Drug Hepatotoxicity*", 11th Congress of the European Association for Clinical Pharmacology and Therapeutics, EACPT 2013, Geneva, Switzerland.
73. 2013 - Session V: "*Inflammation and Innate Immunity II*"; 17th International Symposium on Cells of the Hepatic Sinusoid and 27th Symposium of the Japanese Society of Hepatic Sinusoidal Cell Research, Osaka, Japan.
74. 2013 - Acetaminophen Protein Adduct Forum, McNeil Consumer Health Care; Phoenix, Arizona.
75. 2014 - Symposium: "Clinical evaluation of emerging biomarkers of drug-induced liver injury". 53th Annual Meeting of the Society of Toxicology, Phoenix, Arizona.
76. 2014 - Symposium: "The emerging role of mitochondrial turnover, biogenesis and dynamics in tissue injury." 53th Annual Meeting of the Society of Toxicology, Phoenix, Arizona.
77. 2014 - Session I: "*Understanding the Problem of DILI*", Falk Workshop: "*The Challenge of Drug-induced Liver Injury (DILI)*". Freiburg, Germany.
78. 2015 - 14th Hepatobiliary and Gastrointestinal Research Retreat 2015, Vulpera, Switzerland.
79. 2015 - Experimental Biology, ASIP Symposium: "*Programmed non-apoptotic cell death in tissue injury*", Boston, MA.
80. 2015 - 38th Annual RSA Scientific Meeting. Symposium: "*Alcohol, Neutrophils and Organ Damage*", San Antonio, TX.
81. 2015 - Annual Meeting of the Central States Chapter of the Society of Toxicology, Kansas City, KS. "*Mechanisms of Acetaminophen Hepatotoxicity and Acute Liver Failure in Patients*"
82. 2015 - Pediatric Acute Liver Failure of Undetermined Cause: A Clinical Research Workshop. NIDDK, Bethesda, MD.

83. 2015 - International Conference on Clinical and Translational Research, Beijing, China. "*Acetaminophen Hepatotoxicity and Acute Liver Failure: From Animal Models to Humans*".
84. 2016 - Annual Meeting of the Environmental Mutagenesis and Genomics Society, Kansas City, MO. Session: "*MicroRNAs as biosensors of exposure, disease, and susceptibility: Implications for human health risk evaluation.*"
85. 2017 - 40th Annual RSA Scientific Meeting, Symposium: "*Multi-organ effects of alcohol on the innate immunity*", Denver, CO.
86. 2017 – Annual Meeting of the Japanese Society of Toxicology, Yokohama City, Japan. Symposium: "*Insights into Mechanisms of Drug-induced Liver Injury.*"
87. 2017 – 5th Annual Midwest Stem Cell Meeting, Kansas City, MO. "*Stem Cell Approaches to Promote Liver Repair after Acetaminophen Hepatotoxicity*".
88. 2018 – Eurotox Congress, Brussels, Belgium. Symposium: "*New Insights in the Role of the Innate Immunity in Immunotoxicology*".

Symposia/Workshop Organizer and Session Chairman at National and International Meetings

1. 1995 - Organizer and Co-chair of Symposium "*Mechanisms of Inflammatory Liver Injury: Adhesion Molecules and Cytotoxicity of Neutrophils*"; 34th Annual Meeting of the Society of Toxicology, Baltimore, MD.
2. 1995 - Co-chair, AASLD Early Morning Workshop "*TNF- α in Liver Repair and Disease*", 46th Annual Meeting of AASLD, Chicago, IL.
3. 1996 - Co-chair, Minisymposium "*Sequential Stresses*"; 19th Annual Meeting of the Shock Society, Traverse City, MI.
4. 1997 - Co-chair, Session "*Mechanisms and Modulation of Inflammatory and Infectious Liver Disease*"; 4th Int. Congress on the Immune Consequences of Trauma, Shock and Sepsis, Munich, Germany.
5. 1997 - Co-chair, Meet-the-Professor-Luncheon, "*Role of Adhesion Molecules and Oncogenes in Liver Injury*"; Postgraduate Course, 48th Annual Meeting of AASLD, Chicago, IL.
6. 1997 - Co-chair, Session "*Apoptosis*", 48th Annual Meeting of AASLD, Chicago.
7. 1998 - Chair, Symposium "*Chemokines and Parenchymal Cell Adhesion Molecules*"; 21st Annual Meeting of the Shock Society, San Antonio, TX.
8. 1998 - Co-chair, Session "*Receptors and Endocytosis*"; 9th Int. Symposium on Cells of the Hepatic Sinusoid, Christchurch, New Zealand.
9. 1998 - Co-chair, Session "*Cell Death*"; 49th Annual Meeting of AASLD, Chicago.
10. 1999 - Co-chair, Session "Prävention/Therapie des Ischämie-Reperfusionsschadens"; Int. Symposium *Chirurgie der Lebertumoren – Tumorbiologie, Diagnostic, Therapie*. Munich, Germany.
11. 1999 - Co-chair, Symposium "*Cell Adhesion Molecules*"; 4th Int. Shock Congress, Philadelphia, PA.
12. 1999 - Co-chair, Meet-the-Professor-Luncheon, "*Apoptosis and Human Liver Disease*"; Postgraduate Course, 50th Annual Meeting of AASLD, Dallas, TX.

13. 1999 - Co-chair, AASLD Early Morning Workshop "*Oxidant-mediated Liver Injury*", 50th Annual Meeting of AASLD, Dallas, TX.
14. 2000 - Co-moderator, Poster Discussion Session "*ARDS - Liver injury - Wound Healing in Sepsis*"; 5th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany.
15. 2000 - Co-chair, Session II: "*Inflammation, Mediators & Infection*"; 10th Int. Symposium on Cells of the Hepatic Sinusoid, Southampton, UK.
16. 2000 - Co-chair, AASLD Early Morning Workshop "*Oxidant-mediated Liver Injury*", 51th Annual Meeting of AASLD, Dallas, TX.
17. 2001 - Co-Organizer and Co-chair of Symposium "*Mechanisms of Hepatotoxicity*"; 40th Annual Meeting of the Society of Toxicology, San Francisco, CA.
18. 2001 - Co-chair of Symposium "*Preservation/Reperfusion Injury 2*"; 6th Congress of the International Society for Organ Sharing, Nagoya, Japan.
19. 2001 - Co-chair of Symposium "*Cellular Mechanisms of Inflammation, Ischemia-reperfusion and Necrosis*"; 2nd Int. Conference on Hepatic & Splanchnic Circulation in Health and Disease, Dunedin, New Zealand.
20. 2001 - Co-chair, AASLD Early Morning Workshop "*Oxidant-mediated Liver Injury*", 50th Annual Meeting of AASLD, Dallas, Texas.
21. 2002 - Co-chair of Symposium "*Molecular and Cellular Mechanisms of Ischemic Liver Injury*". Experimental Biology '02, New Orleans, Louisiana.
22. 2002 - Co-Chair of Session "*Non-Parenchymal Cells and Liver Injury*"; 11th Int. Symposium on Cells of the Hepatic Sinusoid, Tucson, Arizona.
23. 2002 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Role of Oxidant Stress in Drug-induced Liver Disease*", 53th Annual Meeting of AASLD, Boston, Massachusetts.
24. 2003 - Organizer and Chair, ISSX Basic Science Course "*Xenobiotic-induced Hepatotoxicity*", Providence, Rhode Island.
25. 2003 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Mechanisms of Drug-induced Liver Injury*", 54th Annual Meeting of AASLD, Boston, Massachusetts.
26. 2003 - Co-Chair, Symposium "*Cell Death*"; 54th Annual Meeting of AASLD, Boston, Massachusetts.
27. 2003 - Co-Chair, Symposium on "*Novel Strategies for Hepatoprotection*"; European Gastroenterology Week, Madrid, Spain.
28. 2004 - Co-Chair, Symposium "*Hepatotoxicity and Hepatoprotection – Pathomechanisms and Novel Therapeutic Strategies*". 6th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany.
29. 2004 - Co-Chair, Session X "*Sinusoidal Cell Inflammation and Hepatotoxicity*". 12th Int. Symposium on Cells of the Hepatic Sinusoid, Bilbao, Spain.
30. 2008 - Co-Chair, Session II "*Kupffer Cells*". 14th Int. Symposium on Cells of the Hepatic Sinusoid, Tromso, Norway.
31. 2008 - Organizer, Annual Meeting of Central States Chapter of SOT, Kansas City.
32. 2009 - Co-Organizer and Co-Chair, Symposium "*The role of inflammation during metabolic liver disease and drug-induced liver toxicity: novel insights*". Annual Meeting of the Society of Toxicology, Baltimore, Maryland.

33. 2009 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Drug-induced Hepatotoxicity*", 60th Annual Meeting of AASLD, Boston, Massachusetts, 2009.
34. 2009 - Chair, Session 5: "*Oxidative Stress and Aging*"; Charleston Conference on Mitochondrial Physiology and Pathobiology, Charleston, South Carolina.
35. 2010 - Co-Chair, Session I: "*Hepatic Sinusoidal Cells and Steatohepatitis*"; 15th International Symposium on Cells of the Hepatic Sinusoid, Pasadena, California.
36. 2011 – Co-Chair, Session IV: "*Hepatotoxicology*"; 1st International HepaRG Workshop, Rennes, France.
37. 2011 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Drug-induced Hepatotoxicity*", 62th Annual Meeting of AASLD, San Francisco, California.
38. 2012 – Co-Chair, Platform Session: "*Acetaminophen Toxicity; Mechanistic and Translational Aspects*"; 51st Annual Meeting, Society of Toxicology, San Francisco, California.
39. 2012 - Co-Organizer (together with John Lemasters and Neil Kaplowitz) of a Single Topic Conference: *Mitochondria and Hepatotoxicity*, American Association for the Study of Liver Diseases, Atlanta, Georgia.
40. 2012 – Chair, Session 5: "Drugs and Viruses", Single Topic Conference: *Mitochondria and Hepatotoxicity*, American Association for the Study of Liver Diseases, Atlanta, Georgia.
41. 2012 – Co-Chair, Session 1B: "The Cellular Processes of Acetaminophen-induced Liver Injury", Single Topic Conference: *Acetaminophen Poisoning*, American Association for the Study of Liver Diseases, Atlanta, Georgia.
42. 2012 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Drug-induced Hepatotoxicity*", 63th Annual Meeting of AASLD, Boston, Massachusetts.
43. 2013 – Co-organizer (together with Jose Manautou), ASPET Symposium on *Acetaminophen-induced Hepatotoxicity*, Experimental Biology, Boston, MA.
44. 2013 – Organizer and Chair, Symposium: "*Molecular Mechanisms of DILI*", The International Liver Congress, Amsterdam, The Netherlands.
45. 2013 - Co-Chair, Session 4 "*Inflammation and Immunity I*" 17th International Symposium on Cells of the Hepatic Sinusoid and 27th Symposium of the Japanese Society of Hepatic Sinusoidal Cell Research, Osaka, Japan.
46. 2013 – Chair, Session I, KUMC Liver Center Alcohol Symposium, Kansas City, Kansas.
47. 2013 - Co-Organizer and Co-chair, AASLD Early Morning Workshop "*Drug-induced Hepatotoxicity*", 64th Annual Meeting of AASLD, Washington, DC.
48. 2014 – Co-organizer (with Alexander Gerbes) of Falk Workshop "*The Challenge of Drug-induced Liver Injury (DILI)*", Freiburg, Germany.
49. 2014 – Co-Chair, Session I, "*Understanding the Problem of DILI*", Falk DILI Workshop, Freiburg, Germany.
50. 2015 – Organizer and Chair, 17th Annual John Doull Toxicology Symposium, Kansas City, KS.
51. 2015 - Co-Chair, Session 38: "*Molecular Mechanisms of Liver Injury and Carcinogenesis*"; 66th Annual Meeting, AASLD, San Francisco, CA.
52. 2016 - Organizer and Chair, 18th Annual John Doull Toxicology Symposium, Kansas City, KS.

53. 2017 – Co-chair, Poster sessions: *Liver I: Mechanisms and Translational Biomarkers and Biotransformation*; 56th Annual Meeting of the Society of Toxicology, Baltimore, Maryland.
54. 2017 – Co-Chair, Session: *Alcohol and Related Liver Injuries*; 19th International Symposium on Cells of the Hepatic Sinusoid, Galway, Ireland.
55. 2017 – Organizer and Chair, *19th Annual John Doull Toxicology Symposium*, Kansas City, KS.
56. 2017 – Co-Chair, Session II: *Opportunities for Diverse Tissue and Organ Repair*; 5th Annual Midwest Conference on Cell Therapy and Regenerative Medicine, Overland Park, KS.

TEACHING**A. Didactic Course Work****University of Tübingen**

- 1984 – 1986 Biochemistry, *Research Seminar of Biochemical Toxicology*; Graduate level course, (2 h per week; 12-15 weeks per semester)
- 1984 Biochemistry, *Oxidative Stress: Pathogenesis and Protective Mechanisms*; University of Tübingen; Graduate level course; conducted 50% of the lectures (24 h).
- 1985 Biochemistry, *Pathobiochemistry: Mechanisms of Cell Injury and Protection*; University of Tübingen; Graduate level course; conducted all of the lectures (15 h).

Laboratory Courses

- 1978-1981 Biochemistry, *Biochemistry Laboratory and Seminars for Medical Students*, Laboratory assistant (5 h per week during the semester)
- 1981-1983 Toxicology, *Course of Pharmacology and Toxicology*; Graduate level course for biochemistry students; supervision of laboratory experiments (20 h per semester)
- 1983 – 1986 Biochemistry, *Advanced Course of Physiological Chemistry and Biochemical Toxicology: Mitochondrial Respiratory Chain and Microsomal Drug Metabolism*. Graduate level course for biochemistry students; seminars, oral examinations and supervision of laboratory experiments (20 h per week; 12-15 weeks per semester).

Texas Medical Center, Houston, TX

- 1989 Toxicology 403, *Introduction to the Basic Principles and Modern Applications of Toxicology*. Dept. Pharmacology, Baylor College of Medicine; Graduate level course; Lectures on Drug Metabolism and Methods in Toxicology (6 h).
- 1991 PH 2175 & GS 130063, *Principles of Toxicology*, University of Texas, School of Public Health, Houston; Graduate level course; Lectures on Biotransformation and Toxic Responses of the Liver (6h).

University Arkansas for Medical Sciences

- 1999 - 2000 PCOL/INTX 5041, *Scientific Communications and Ethics*, Course Director; Lectures on Manuscripts and Grant proposal writing (1 h), group discussions and oral presentations (15 h).

- 1999 - 2001 INTX 509V, *Advanced Toxicology*, Course Director and Lectures on Drug Hepatotoxicity (2 h) and Oxidant Stress Defense Mechanisms (2 h).
- 2000 – 2002 500V, *Medical Pharmacology*; Lectures on Toxic Responses of the Blood (1 h) and Chelators & Heavy Metal Toxicity (1 h); 10-12 case conferences (20-24 h).
- 2000 - 2001 Journal Club “*Mechanisms of Cell Death and Liver Pathophysiology*”.
- 2000 – 2002 PCOL/INTX 6663, *Molecular Pharmacology & Toxicology*, 4 lectures on Molecular Mechanisms of Inflammation (6 h).
- 2001 – 2002 INTX 5063, *Toxicology for Graduate Students*, lecture on Molecular Mechanisms of Cell Injury (1.5h) and 3 lectures on Mechanisms of Hepatotoxicity (4.5h).
- 2001 PCOL/INTX 5033, *General Principles of Pharmacology and Toxicology*, Lectures on Mechanisms of Cell Injury (2 h) and Mechanisms of Cell Death (2 h).

University of Arizona

- 2003 – 2004 PCOL 610, *Molecular and Cellular Toxicology*, Lectures on Cell-Cell Interactions in Liver Injury (2 h).
- 2004 PCOL 573, *Environmental Toxicology Colloquium*, lecture on Liver Toxins (1 h).
- 2005 – 2006 PHCL 551a, *Molecular Targets of Pharmacological Agents*, Lectures and discussions on Cytokines and their Receptors (Structure, Function, Inflammation), COX Inhibitors, and Drug Development (6 h).

University of Kansas Medical Center

- 2007 – present PTOX 918, *Toxicology Course*, Lectures on “Hepatotoxicity” (2007-present), Kidney Toxicity (2007), Plant and Animal Poisons (2007) (2 h each).
- 2008 – 2009 Integration and Consolidation Module in the 2nd Year Curriculum, Medical School, Lectures on drugs action on autocooids: “Histamine, Serotonin and Ergot Alkaloids” and “Prostaglandins, Leukotrienes and NSAIDS”; Drug treatment of “Asthma”, “Arthritis”, “Allergies and Migraines”, “GI Disorders” (6 h).
- 2008 Small Group Case Discussions, Medical School (16 h)
- 2008 – present PTOX 887, *Toxicologic Pathology*, Course Director and Lectures on “Oxidant stress and antioxidant defense” (2 h) and “Mechanisms of oncotic necrosis” (4 h).
- 2014 - present PTOX 917, *Drug Metabolism and Disposition*, Lecture on “Conjugation I and II” (2h).

B. Non-Didactic TeachingCOBRE Mentor for Junior Faculty

- Dr. Jim Luyendyk (received Ones Award, NIEHS in 2009)
- Dr. Wen-Xing Ding (received R01, NIAAA, 2011)
- Dr. Udayan Apte (received Liver Scholar Award, American Liver Foundation, 2009)
- Dr. Udayan Apte (received R01, NIDDK, 2013)
- Dr. Michele Pritchard (August 2012 – present)

Post-Doctoral Fellow Training

- | | |
|-------------------------------|------------------------------|
| - Dr. Rochus Witthaut | July 1992 - December 1992 |
| - Dr. Peitan Liu | August 1992 - July 1994 |
| - Dr. Charles Ying Wang | May 1994 - April 1996 |
| - Dr. Naeem Essani | October 1993 - December 1996 |
| - Dr. Tadashi Hasegawa | November 2003 – March 2006 |
| - Dr. Jayanthi Wijeweera | July 2004 – August 2006 |
| - Dr. Ji-Young Hong | March 2007 – January 2009 |
| - Dr. Min Yang | July 2008 – June 2012 |
| - Dr. Clarence David Williams | August 2012 – November 2013 |
| - Dr. Mitchell R. McGill | July 2013 – June 2015 |
| - Dr. Benjamin L. Woolbright | March 2015 – March 2017 |

Graduate Student Training (Thesis Advisor)

- | | |
|---|----------------------------|
| - Christin Kleinwaechter (Masters Thesis) | April 1984 - December 1984 |
| - Christin Kleinwaechter (PhD Thesis) | January 1985 - August 1986 |
| - Christoph Werner (Masters Thesis) | August 1985 - June 1986 |
| - Jaspreet Gujral (PhD Thesis) | Sept. 1999 – February 2004 |
| - Tamara Knight (PhD Thesis) | January 2000 – May 2004 |
| - Chieko Saito (PhD Thesis) | Sept. 2006 – January 2010 |
| - Clarence David Williams (PhD Thesis) | May 2008 – July 2012 |
| - Mitchell McGill (PhD Thesis) | July 2009 – April 2013 |
| - Ben Woolbright (PhD Thesis) | April 2011- February 2015 |
| - Yuchao Xie (PhD Thesis) | May 2011 – May 2016 |
| - Kuo Du (PhD Thesis) | May 2012 – December 2016 |
| - James Weemhoff (PhD Thesis) | May 2013 – October 2017 |
| - Luqi Duan (PhD Thesis) | May 2015 – present |
| - Jephthe Akakpo (PhD Thesis) | May 2016 – present |

Graduate Student Training (Dissertation Committee Member)

- | | |
|--------------------------------------|----------------------------|
| - Jian Chang (Pharmacology, Baylor) | September 1988 - June 1993 |
| - Paul Nony (Toxicology, UAMS) | July 2000 – June 2001 |
| - James Yu (Pharmacology, UAMS) | July 1999 – August 2002 |
| - Xiuli Liu (Toxicology, UAMS) | May 2000 – April 2002 |
| - Shary Shelton (Pharmacology, KUMC) | July 2007 – June 2010 |
| - Mary Shawgo (Pharmacology, KUMC) | July 2007 – August 2009 |
| - Katryn Allen (Toxicology, KUMC) | July 2007 – April 2011 |

- Ming Xu (Allied Health, KUMC)	May 2008 – August 2011
- Brad Sullivan (Toxicology, KUMC)	August 2011 – July 2012
- Chad Walesky (Toxicology, KUMC)	May 2011 - March 2014
- Jessica Williams (Toxicology, KUMC)	June 2011 – May 2015
- Bharat Bhusan (Toxicology, KUMC)	July 2012 – June 2016
- Samikshya Poudel (KUMC) <i>Masters Thesis</i>	July 2015 – August 2016
- Jennifer McCracken (Toxicology, KUMC)	July 2014 – May 2017
- Asand Saran (Toxicology, KUMC)	July 2014 – present
- Steven McGreal (Toxicology, KUMC)	Oct 2014 – October 2017
- Yuan Li (Toxicology, KUMC)	July 2015 – present
- Prachi Borude (Toxicology, KUMC)	July 2015 – November 2017
- Ian Huck (Toxicology, KUMC)	July 2015 - present

Graduate/Medical Student Training (Research Rotations)

- Jaspreet Gujral (UAMS)	Fall 1999
- Tamara Knight (UAMS)	Winter 2000
- Jean Lord (UofA)	Summer/Fall 2003
- Chieko Saito (UofA)	Spring 2006
- Huimin Yan (KUMC)	Spring/Summer 2007
- Clarence David Williams (KUMC)	Spring 2008
- Mitchell McGill (KUMC)	Summer 2009
- Michael Koerner (Univ. Illinois at Chicago; COM)	Summer 2010
- Yuchao Xie (KUMC)	Fall 2010
- Debra Salmon (UofA)	Fall 2010
- Ben Woolbright (KUMC)	Winter 2011
- Bharat Bhushan (KUMC)	Spring 2011
- Kuo Du (KUMC)	Winter 2012
- Chad Pope (KUMC)	Spring 2012
- Nathan Mendoza (KUMC)	Summer 2012
- James Weemhoff (KUMC)	Fall 2012
- Samikshya Poudel (KUMC)	Fall 2013
- Jesal Amin (UMKC)	Summer 2014
- Miki Katuwal (KUMC)	Fall 2014
- Prabhakar Bastola (KUMC)	Winter 2015
- Luqi Duan (KUMC)	Spring 2015
- Sachith Polpitiya Arachchige (KUMC)	Summer 2015
- Jephthe Akakpo (KUMC)	Spring 2016

Research Associates

- Martina Fausel (1983-1986)	University of Tübingen
- Marilyn Owens (1986-1987)	Baylor College of Medicine
- Samuel Whyllie (1987-1988)	Baylor College of Medicine
- Michael Fisher (1988-1998)	Baylor College of Medicine/The Upjohn Co.
- Brad Black (1989-1991)	Baylor College of Medicine
- Gerald McGuire (1992-1995)	The Upjohn Company
- Judy Lawson (1996-1998)	Pharmacia & Upjohn

- Robert Hopper (1999-2001) University of Arkansas
- Cathleen Cover (2004-2006) University of Arizona
- Margitta Lebofsky (2006-present) University of Kansas Medical Center
- Huimin Yan (2007-2012) University of Kansas Medical Center

Research Faculty

- Dr. Mary Lynn Bajt (UAMS, UofA, KUMC) 1999 - present
- Dr. Anup Ramachandran (KUMC) 2009 – 2012; 2015-present

Undergraduate Student Training

- 1988-1990, mentor in Co-op program of the Department of Biochemistry, Texas A&M University, to train undergraduate students for 3 semesters (Eric Benzick).
- 1990 - 1992, mentor in SMART Summer program and Minority Programs (Baylor College of Medicine/Rice University, Houston, Texas) with a total of 6 summer students.
- 1993 - 1998, mentor for "Senior Individualized Project" (Kalamazoo College and Lee Honor College of Western Michigan University) total of 6 students.
- 2000, mentor for undergraduate summer student (Angela Kurtz, Valparaiso College)
- 2001, mentor for science project of Shannon Palmer, high school student from the Arkansas Mathematics and Science School, Hot Springs, AR.
- 2011, mentor for research internship of undergraduate biology student LeAndrea Wilson, University of Kansas.
- 2017, mentor for Jake Kwon for summer research internship, supported in part by SOT.